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Abstract: 
           Various  substituted   1,3,4-oxadiazole  and 1,3,4-thiadiazole derivatives have  
been  synthesized  by  cyclising  semicarbazone and thiosemicarbazone   in presence of  ferric 
chloride and citric acid to form 2-amino-5-substituted 1,3,4-oxadiazole and 1,3,4-thiadiazole  
respectively. These derivatives undergoes  mannich reaction  with  substituted  aniline and  
formaldehyde to form 2-amino5-substituted1,3,4-oxadiazole and  1,3,4- thiadiazole 
derivatives. The identity  of compounds were  confirmed  on  the  basis of their  
spectral(IR,1H NMR  and MASS) data. Further, they have been screened for their 
antibacterial, antifungal, anticancer and antitubercular activities. 
  
Keywords:  
             1,3,4-oxadiazoles,1,3,4-thiadiazoles,antibacterial,antifungal,antitubercular,anticancer. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
               Pharmaceutical chemistry is a science that makes use of the general laws of 
chemistry to study drugs, i.e. their proportion, chemical nature, composition, influence on an 
organism and studies of the physical and chemical proportion of drugs, the methods of 
quality control and the conditions of their usages. In   other  words ,it  is  the  chemistry  of  
drugs. Drugs  mainly  exert  action  depending  upon  the  biochemical  pathway. 
           Pharmaceutical chemistry  is  a  specialized  science  which  depends  on  the  other   
disciplines  such  as inorganic, organic, analytical, physical  and colloid  chemistry  and  also  
on  medico-biological  disciplines  such  as  pharmacology, physiology, biological  chemistry  
etc. 
             Pharmaceutical  chemistry   occupies  the  most  important  place  among  the  related  
sciences  such  as  drug  technology, toxicology  chemistry, pharmacognosy,  the  economy  
and  the  organization  of  pharmacy. 
          The very breadth of knowledge required by a medicinal chemist is both a challenge and 
a reward.  Mastering and understanding of such a breadth of subject areas is no straight 
forward task, but by the same token there is ample intellectual stimulation in understanding 
the battle against disease at the molecular level and in designing molecular ′soldiers′ to win 
the battle. 
         Molecular biology and genetic engineering have produced a deluge of potential new 
target for drug design and have unraveled the structures and mechanisms of traditional targets 
while advances in computers and computer aided design have allowed medicinal chemists to 
take full advantage of this newly earned knowledge.  
          Chemical modification of drug molecules to locate the number of series having optimal 
effects and will probably continued to be the factor necessary, to make new drugs.  To 
establish the structure of the drug molecules the new invention in the physico-chemical 
directions such as X-ray crystallography different types of chromatography, spectroscopic 
studies like NMR, IR, Mass, U.V immensely helpful for medicinal chemist.  
        The advances in the molecular biology, computer science, instrumentation technology 
gave an revolutionary turn to concept of chemotherapy leading to development or other area 
of drug design, QSAR studies etc. 
 
 
        Oxadiazole  derivatives  are well  known  to  have  number  of  biological  and 
antimicrobial  activities. This  also  having  anti-inflammatory, antitubercular, anticancer  and  
anticonvulsant  activities.  
        Thiadiazole  and  oxadiazoles   were  reported   to  possess   various  pharmacological  
activity  of   clinical  impotence. Discovering  new  drugs   has  never  been  a  simple  matter. 
In  view  of  above considerations   we  have  selected Tailor made  approach  of  drug  design  
in  search  of new  potent  bioactive  drug  molecules.  
A diversity of useful biological effects is possessed by heterocyclic compounds containing 
oxadiazole nucleus. Heterocyclic Compounds having a five member ring containing one 
oxygen and two Nitrogen are called Oxadiazole or in the older literature Furadiazole. [1]  
 
 
 
 
In Oxadiazole class 1,3,4- oxadiazole has gradually become prevalent and was used 
exclusively.  
1,3,4-oxadiazoles  having  many biological activities including, Antioedema and Anti-
inflammatory activity[2,3,4,5], Analgesic[3,4] Antimicrobial[6,7] Antitubercular[8] 
Antifungal, Anticonvulsant[9] , Antihypoglycemic, Anticancer[10,11], Antileishmanial, 
Antimalarial, Antiviral, , and Insecticidal properties.A literature survey also reveals that 
several 1, 3, 4-oxadiazole derivatives are active against Mycobacterium. The current work 
describes the synthesis of 1,3,4-oxadiazoles and evaluates the Antibacterial, Antifungal and 
Antimycobacterial activity against M. tuberculosis H37Rv. 
 
 
 
 
 
 
 
                          SAR for 1,3,4- Oxadiazole   and  1,3,4-thiadiazole 
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Exhaustive SAR studies have been conducted with the 1, 3, 4-oxadiazole  and 1,3,4-
thiadiazole  derivatives.  
 
 The 2-position and 5-position is an extremely important site of molecular 
modification, which play a dominant role in determining the pharmacological 
activities of 1, 3, 4-oxadiazole  and 1,3,4- thiadiazole derivative. 
 Direct substitution of the 2-position with a 2-methoxy phenol, pyridine and benzoic 
acid, with pyridine in 5-position enhance the antimicrobial activity of 1, 3, 4-
oxadiazole and 1,3,4-thiadiazole  derivative. 
 Substitution of the 2-position with an methoxybenzene, ethenylbenzene and benzoic 
acid, with pyridine in 5-position enhance the analgesic activity of 1, 3, 4-oxadiazole 
and 1,3,4-thiadiazole  derivative. 
 Direct substitution of the 2-position with an amino benzene and benzoic acid, with 
pyridine in 5-Position enhance the anti-inflammatory activity of 1, 3, 4-oxadiazole 
and  1,3,4-thiadiazole  derivative. 
 Direct substitution of the 2-position with a 2-methoxy phenol, pyridine and benzoic 
acid, with pyridine in 5-position enhance the Tuberculostatic Activity of 1, 3, 4-
oxadiazole and  1,3,4-thiadiazole derivative. 
 
 
 
                     1,3,4-OXADIAZOLE  as medicinal agent 
 
Code Name Structure IUPAC        Uses 
1 Butyl PBD 
 
2-(4-tert-
Butylphenyl)-
5-(4-
phenylphenyl)-
1,3,4-
oxadiazole 
In the liquid scintillator 
neutrino  detector. 
2 SL65.0155 
 
 
5-(5-amino-
6-chloro-2,3-
dihydro-1,4-
benzodioxin-
8-yl)-3-(1-
phenethyl-4-
piperidyl)-
1,3,4-
oxadiazol-2-
one 
hydrochloride 
is a  selective 5-HT4 
receptor  partial agonist. It 
potently enhance 
cognition,learning,memory 
and also possesses 
antidepressant effects. 
3 SX-3228 
 
(3E)-6-
benzyl-3-(5-
methoxy-
1,3,4-
oxadiazol-
2(3H)-
ylidene)-
5,6,7,8-
tetrahydro-
1,6-
naphthyridin-
2(3H)-one 
Is a sedative and 
hypnotic and with 
only limited 
anxiolytic effects 
which appear only 
at doses that also 
produce significant 
sedation. 
 
 
 
 
 
                   1,3,4-THIADIAZOLE   as   medicinal agent 
 
Code Name Structure IUPAC        Uses 
1 Cefazedone 
 
(6R,7R)-7-{[2-(3,5-
dichloro-4-oxopyridin-1-
yl) 
acetyl]amino}-3-[(5-
methyl-1,3,4-thiadiazol-2-
yl) 
sulfanylmethyl]-8-oxo-5-
thia-1-azabicyclo[4.2.0] 
oct-2-ene-2-
carboxylic acid 
It is used in 
the treatment 
of respiratory 
and urinary 
tract 
infections 
2 Cefazolin 
 
(6R,7R)-3-{[(5-methyl-
1,3,4-thiadiazol-2-
yl)thio]methyl}-8-oxo-7-
[(1H-tetrazol-1-
ylacetyl)amino]-5-thia-1-
azabicyclo[4.2.0]oct-2-
ene-2-carboxylic acid 
Cefazolin is 
mainly used to 
treat bacterial 
infections of the 
skin. It can also 
be used to treat 
moderately 
severe bacterial 
infections 
involving the 
lung, bone, joint, 
stomach, blood, 
heart valve, and 
urinary tract.  
3 Methidathion 
 
3-
(dimethoxyphosphinothioylsul
fanylmethyl)-5-methoxy-
1,3,4-thiadiazol-2-one 
is an 
organophosphate 
insecticide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
  
In the family of Heterocyclic compounds, containing Nitrogen, Oxygen atom and 
Sulphuratom are considered as an important class of compounds in Medicinal Chemistry 
because of their interesting diversified Biological application. During the past years 
considerable evidences have also accumulated to demonstrate the efficacy of 1, 3, 4-
oxadiazoles and  1,3,4-thiadiazoles including Antibacterial, Anti-inflammatory, Anti 
malarial, Antitubercular, Anti hypoglycemic, Anticancer, Antileishmanial, Antialzheimer, 
Antiviral, Anticonvulsant and Insecticidal properties. Literature survey revealed that slight 
modification in the structure can result in qualitative as well as quantitative changes in the 
activity, which prompted us to undertake the synthesis of various new 2-amino-5-substituted-
1, 3, 4-Oxadiazole derivatives with the aim of having improved activity and lesser toxicity. 
The review of literature reveal also prompted us to synthesize substituted Oxadiazole  and  
thiadiazole compounds and those will be screened for Antimicrobial activity to get potent 
bioactive molecule. It is well known that introduction of atom like chlorine, bromine, nitro 
etc in organic molecule causes dramatic change in its biological profile.The synthesized 
compound will be screened for anticancer activity and antitubercular activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oxadiazole as Anticancer agents 
  
Xiao-Min Zhang etal[13] synthesized a  series of  novel 1,3,4-oxadiazole derivatives 
containing 1,4-benzodioxan moiety (6a–6s)   as potential telomerase inhibitors were 
synthesized. compound 6k possessed the most potent telomerase activity . 
  
 
 
 
Linhong Jin,etal[14] synthesized a series of 3-acetyl-2-substituted phenyl-5-(3,4,5-
trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives . The IC50 values of high active 
compounds 2a, 2b, 2c, 2f, 3l, and 3m against PC3 cells  and are moderately active against 
Bcap37 and BGC823 cells. 
  
 
 
Hai-Liang Zhu etal[15] synthesized a  series of   a  series of new 2-chloropyridine derivatives 
possessing 1,3,4-oxadiazole moiety were synthesized. Antiproliferative  assay   results    
indicated  that compounds 6o and 6u exhibited the most potent activity against gastric cancer 
cell  which was more potent than the positive  control. 
  
  
 
 
 
 
.      Where6k=2-Me-C6H4  
 
Rajyalakshmi Gudipati etal[16]  synthesized  A series of 5- or 7-substituted 3-{4-(5-
mercapto-1,3,4-oxadiazol-2-yl)phenylimino}-indolin 2-one derivatives were synthesized by 
treating 5-(4-aminophenyl)-1,3,4-oxadiazole-2-thiol. 
  
 
Xiaoling Chen etal[17] synthesized 1,3,4- Oxadiazole derivatives were synthesized and 
evaluated for their ability to inhibit tubulin polymerization and to cause   mitotic arrest in 
tumor cell. 
 
 
 
Figure   R1=4-Fluorophenyl,R2=2,3-dihydro benzo-1,4-dioxin-6yl,R3=H shows activity in 
tumour cell lines. 
 
M.A. Abu-Zaie  etal [18]  synthesized  of  novel 1,3,4-oxadiazole condense with O-
aminothiols  to  give  the   bases   8, 19 and 20   in   good   yields,   respectively. 
Pharmacological    evaluation  of     compounds   8, 14, 16 and 22   in vitro against 2-cell  
lines  MCF-7  (breast)  and  HEPG2  (liver)  revealed   them to possess  high anti-tumor 
activities  with  IC50 values  ranging  from  2.67e20.25 (mg/mL)  for breast  cell line (MCF-
7) and  4.62e43.6 (mg/mL) for  liver cell line  (HEPG2). 
 
 
 
  
 
 
Xiaohu Ouyang et.al[19]  Synthesized a series of 1, 3, 4 oxadiazoles and are evaluated for 
their ability to inhibit tubulin polymerization and to arrest mitotic division of tumor cells. 
Among these synthesized compounds, some compound showed potent activity. 
  
Fig: 3-(5-(benzo[d][1, 3]dioxol-5-ylamino)-1,3,4-oxadiazol-2-yl)-N-(pyridin-4-
ylmethyl)pyridin-2-amine 
 
 
B Shivarama holla et.al[20] Synthesized  2chloro 1,4 bis-(5-sustituted 1,3,4 oxadiazole-2-
ylmethylenoxy) phenylene derivative and these compound have been extensively screened  
against a panel of sixty cancer cell lines derived from leukemia, prostrate,  colon , lung, CNS, 
ovarian, melanoma and breast cancer respectively. Compound 3d and 3f shows potent 
Anticancer activity against most of the cell lines with GI50 values <s100 µM concentrations. 
 
  
 
Fig: 2chloro 1, 4 bis-(5-sustituted 1, 3, 4 oxadiazole-2-ylmethylenoxy) phenylene derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maryam Zahid etal[21] Synthesized a series of Adamantanyl-1, 3-thiazole and 1,3,4-
oxadiazole derivatives (6a-l), bearing various aryl groups has been synthesized from 
adamantan-1-nitrile in four steps. All the compounds were evaluated, in vitro, for Anti 
proliferative activity against a large panel of human tumor-derived cell lines. Compounds 6e 
exhibited activity against human spleenic lymphoblastoid (WIL-2NS) and human acute B-
lymphoblastic leukemia (CCRF-SB) cell lines with CC
50 
= 68 and 42µM, respectively. 
Compound 6l showed activity against CCRF-SB cell lines with CC
50 
= 51 µM. All the other 
compounds were found inactive. 
  
 . 
FIG: 2-(2-adamantyl-1, 3-thiazol-4-yl)-5-aryl-1, 3, 4-oxadiazoles. 
 
Aboraia AS et al[22] Synthesized a series of 5-(2-hydroxyphenyl)-3-substituted-2,3-dihydro-
1,3,4-oxadiazole-2-thione derivatives were evaluated for their in-vitro Anticancer activity, 
where seven out of twenty two synthesized compounds displayed high Anticancer activity, in 
the primary assay. These seven oxadiazole compounds were selected for a full Anticancer 
screening against a 60-cell panel assay where they showed non-selective broad spectrum and 
3a 4ClC6H4 
3b 4NO2C6H4 
3c 4ClC6H4OCH2 
3d 2,4Cl2C6H3OCH2 
4a 4ClC6H4-furanyl 
4b 4NO2 C6H4-furanyl 
4c 2,4Cl2 C6H3-furanyl 
4d 4-NO2-2-CH2 C6H3-
furanyl 
 
 
promising activity against all Cancer cell lines. As a result of 60-cell panel assay two 
oxadiazole compounds were identified as promising lead compounds. 
  
 
Fig: 3-((3-chlorophenylamino)methyl)-5-(2-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)- 
thione 
 Oxadiazole as AntiDiabetic 
  
Hanna et al [23]  Synthesized a series of novel 1, 3, 4 oxadiazole derivatives and evaluated for  
hypoglycemic activity  and the  synthesized compounds have good hypoglycemic activity. 
 
  
 
Hussain et al [24]    Synthesized a series of 2-arylamino-5-(2 naphthyloxymethyl)-1, 3, 4-
oxadiazole derivatives has exhibited considerable Oral Hypoglycemic activity. 
  
 
 
           Fig: 2-arylamino-5-(2-naphthyloxymethyl)-1, 3, 4-oxadiazole derivative 
 
Husain MK and Jamali MR, [25] Synthesized a series of 1, 3, 4-oxadiazole analogues i.e., 2-
arylamino-3-p-(3-aryl-4-oxaquinozolin-2-yl (methylamino) phenyl-1,3,4-oxadiazoles has 
been found to possess Oral Hypoglycemic activity. 
 
 
 
  
          Fig: 2-arylamino-3-p-(3-aryl-4-oxaquinozolin-2-yl (methylamino) phenyl-1, 3, 4-oxadiazoles 
 
A series of 2, 5-disubstituted 1, 3, 4-oxadiazoles derivatives with different Substituent’s were 
synthesized for their hypoglycemic activity 
 
 
 
 Oxadiazole as Anticonvulsant  
 
Omar Amme and Aboulwafa om,[26]  Synthesized a novel series of 2-substituted amino-5-
aryl1, 3, 4-oxadiazole derivatives were synthesized and screened for their anticonvulsant 
properties.  
  
                                           Fig: 2-substituted amino-5-aryl-1, 3, 4-oxadiazol 
Zarghi et al[27]  Synthesized a series of 2-substituted-5-(2-benzyloxyphenyl)-1, 3, 4-
oxadiazole derivatives were synthesized and evaluated as Anticonvulsant agent. 
  
            Fig: 2-substituted-5-(2-benzyloxyphenyl)-1, 3, 4-oxadiazole derivatives 
Choudhary etal[28] synthesized some Mannich bases like 5-(3,4-methylenedioxyphenyl)-3-
arylaminomethyl-1,3,4-oxadiazole-2-thiones, were synthesized for their Anticonvulsant 
properties. 
 
 
  
                             Fig: 5-(3, 4-methylenedioxyphenyl)-3-arylaminomethyl-1, 3, 4-oxadiazole-2-thiones 
 
Almasirad A etal[29] synthesized some of the compounds i.e., 2-substituted-5-[2-(2-
fluorophenoxy) phenyl]-1, 3, 4-oxadiazoles and -1, 2, 4-triazoles showed considerable 
Anticonvulsant activity in PTZ and MES models. 
 
 
Kim RM  etal[30]    Synthesized a series of  HIV-1 protease inhibitors (PI’s) bearing 1,3,4-
oxadiazoles at the P1' position were synthesized by a novel method involving the 
Diastereoselective installtion of a carboxylic acid and conversion to the P1' heterocycle 
exhibited excellent activities. 
 
 
Ali A. El-Emam[31] Synthesized a series of 5-(1-adamantyl)-3-arylaminomethyl- 1,3,4-
oxadiazoline-2-thiones 4a–m or 5-(1-adamantyl)-3-(4-substituted-1-piperazinylmethyl)-1,3,4-
oxadiazoline-2-thiones 5a–h, The inhibitory activity of compounds 2, 4a–m, and 5a–h against 
Human Immunodeficiency virus type 1 (HIV-1) was determined using the XTT assay in MT-
4 cells. 
 
 
                        
   
4a=H
4b=2-F
4c=4-F
4d=2-Cl
4e=4-Cl
4f=2-Br
4g=4-Br
4h=3-NO2
4i=4-NO2
4j=4-CH3O
4k=2-CN
4l=2-CF3
4m=2,5-F2
5a=CH3
5b=C2H5
5c=COOC2H5
5d=C6H5
5e=4-FC6H4
5f=2-CH3OC6H4
5g=C6H5CH2
5h=2-CF3C6H4CH2
 
 
Fig: 5-(1-adamantyl)-3-arylaminomethyl-1,3,4-oxadiazoline-2-thiones 4a–m or 5-(1-adamantyl)-3-(4-
substituted-1-piperazinylmethyl)-1,3,4-oxadiazoline-2-thiones 5a–h, 
 
R. Iqbal etal[32]    Synthesized Twelve novel primary and secondary Benzene sulfonamides 
bearing 2,5-disubstituted-1,3,4-oxadiazole moiety. Some of the synthesized compounds (4d, 
4e, 4f) have been screened in vitro for their anti-HIV activity; the results were in accordance 
with SAR. 
 
  
Fig: 3-(5-mercapto-1, 3, 4-oxadiazol-2-yl) benzene sulfonamide derivatives. 
   
 
 
 
 
 Oxadiazole as Analgesic and Anti-inflammatory  
Jayashankar etal.[33] Synthesized a series of novel ether- linked bis(heterocycle)s. all the 
synthesized compounds were screened for Anti-inflammatory and analgesic activities,7d and 
7g showed excellent activity than Ibuprofen and Aspirin. 
 
  
        Fig:  2-(((4, 5-dihydroisoxazol-5-yl)methoxy)methyl)-1,3,4-oxadiazole 
 
Shashikant V. Bhandari etal[34] Synthesized a series of S- substituted phenacryl 1,3,4 
oxadiazole  and Schiff bases derived from 2-[(2,6-dicloroanilino)phenyl acetic acid], 
(Diclofenac acid) were found to have significant Anti-inflammatory activity with significant 
analgesic activity  acetic acid induce Writhing models with no Ulcerogenic activity , those 8 
active compounds found to have most prominent and consistent Anti-inflammatory activity. 
 
  
 
Fig:  S-substituted phenacryl 1, 3, 4 oxadiazole and schiff bases derived from 2-[(2, 6-dicloroanilino) phenyl 
acetic acid] 
Mohd Amir etal[35] Synthesized a series of new 1, 3, 4 oxadizole derivatives and 1, 2, 4 
triazine-5-one derivatives. All compounds were screened for their Anti-inflammatory activity 
by using Carrageenin- induced rat paw edema method. Compounds synthesized shown 
maximum Anti-inflammatory activity. 
  
          Fig: 2-((2, 4, 6-trichlorophenoxy) methyl)-1,3,4-oxadiazole derivatives. 
 
 
 
 Harish Rajak, Kramer etal[36] synthesized a series of 1, 3, 4-oxadiazole derivatives have 
found to exert their anti-inflammatory effect via Cyclooxygenase and 5-Lipoxygenase 
inhibitory activity.  
  
 
Nigam etal[37]  Synthesized a series of 2-thio-3-(substituted-amino methyl)-5-(3, 5-
dinitrophenyl)-1, 3, 4-oxadiazoles has been found to possess considerable Anti-inflammatory 
property. 
  
                               Fig: 2-thio-3-(substituted-aminomethyl)-5-(3,5-dinitrophenyl)-1,3,4-oxadiazoles 
 
Burbulien N etal.[38] Synthesized a series of  5-[(2-disubstitutedamino-6-methyl-pyrimidin-
4-yl)-sulfanylmethyl]-3H-1,3,4-oxadiazole-2-thiones  among these he found that some of 
these derivative were much more potent than Ibuprofen. 
  
 
           Fig: 5-[(2-disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanylmethyl]-3H-1, 3, 4-oxadiazole-2-
thiones 
 
Asif HusainMohammed Ajmal etal[39] Synthesized a novel series of 2-[3-(4-
bromophenyl)propan-3-one]-5--(substituted phenyl)-1,3,4-oxadiazoles (4a-n) have been 
synthesized from 3-(4  bromobenzoyl)propionic acid  with the aim to get better Anti-
inflammatory and Analgesic agents with minimum or without side effects (ulcerogenicity). 
 
 
 
  
 
 
      R: C6H5 -, 2-ClC6H4 -, 4-ClC6H4 -, 2-HOC6H4-, 4-NO2C6H4-, 4-FC6H4-,4-CH 3C6H4 -, 4-OCH3C6H4 -, 3,4-
(OCH3)2C6H3-, C6H5CH2-,C6H5OCH2 -, 2-C6H5COC6H4-, 1-C10H7OCH2-, 2-C10H7OCH2- 
 
             Fig: 2-[3-(4-bromophenyl) propan-3-one]-5--(substituted phenyl)-1, 3, 4-oxadiazoles 
 
Dhansay Dewangan1, Alok Pandey  etal[40]   Synthesized a series of novel 1,3,4 oxadiazole  
such as 3 (3a-3e) and 4 (4f-4j) and screened for anti-inflammatory and analgesic activity 
compound 4g and 4j was found to possess better activity then others. 
 
 
 
Oxadiazole as  Antialzheimer 
      
Morihisa Saitoh etal[41]  have been reported  synthesis and structure–activity relationships  
of 1,3,4-oxadiazole   derivatives  as  novel  inhibitors  of  glycogen synthase  kinase-3b  is  
implicated    in  abnormal   hyperphosphorylation  of  tau protein  and its inhibitors are 
expected to be a promising therapeutic agents for the treatment of Alzheimer’s disease. The 
synthesized  compound 20x  showed  highly selective and   potent GSK-3b inhibitory activity 
in vitro . 
 
 
 
  
Where    
  
Oxadiazole  as Antimicrobial 
 
 Mohammed Afroz Bakht  etal[42]  have  been  reported  the molecular properties 
prediction,  synthesis  and  antimicrobial activity of  some  newer 1,3,4- oxadiazole 
derivatives  were  synthesized  and    characterized by IR, NMR and mass spectral analysis  
followed  by  antibacterial  and  antifungal  screening.  It  was  observed  that   compounds  
showed  moderate   to  good    antibacterial  activity,  but     their antifungal  activity        was    
somewhat       moderate.    Compounds   AB13   and AB20 showed    pronounced  activity  
against  all        bacterial and  fungal strains. 
  
 
 
Jignesh P. Raval  etal[43]  synthesized  series of 2(4pyridyl)5[(aryl/heteroarylamino)-1-
oxoethyl]thio-1,3,4-oxadiazole the synthesized compounds, compounds 2(pyridyl)-5((2-
nitrophenylamino)-1-oxoethyl)thio-1,3,4-oxadiazole (5e), 2(4-pyridyl)-5((4-
 
 
nitrophenylamino)-1-oxoethyl)thio-1,3,4-oxadiazole (5g) and 2(4-pyridyl)-5((2-
pyrrolylamino)-1-oxoethyl)thio-1,3,4-oxadiazole (5k) produced highest efficacy and 
exhibited >90% inhibition at a concentration of 0.0077, 0.0052 and 0.0089 lM, respectively. 
All the new compounds were pharmacologically evaluated for their in vitro Antimicrobial 
activity. 
  
  
 
Rakesh Chawla, Anshu Arora  etal [44]    Synthesized 3-acetyl-5-(3-chloro-1 benzo 
[b]thiophen-2-yl)-2-substituted phenyl-2,3-dihydro-1,3,4-oxadiazoles and 2-(3-chloro-1-
benzo[b] thiophen-2-yl)-5-substituted phenyl-1,3,4-oxadiazole and was evaluated for 
Antimicrobial activity. Compound 4c and 4e were found to be most potent, even better than 
standard drug i.e. Ciprofloxacin. 
  
 
Fig: acetyl-5-(3-chloro-1 benzo [b]thiophen-2-yl)-2-substituted phenyl-2,3-dihydro-1,3,4-
oxadiazoles    and 2-(3-chloro-1-benzo[b] thiophen-2-yl)-5-substituted phenyl-1,3,4-
oxadiazole derivative 
 
Chandrakant etal [45]    Synthesized a series of new 1,3,4 oxadiazole with 2-fluoro-4 
methoxy moiety and are tested for Antimicrobial activity, Compound 4a and 4b from all 
synthesized compounds showed significant Antibacterial activity against Escherichia coli and 
Pseudomonas aeruginosa, 4i showed good      Antifungal activity against C. albicans. 
 
 
                                    
 
Mohamed Ashraf Ali and Mohammad Shaharyar etal [46] Synthesized a series of 
Oxadiazole Mannich bases by reaction between Oxadiazole derivatives, Dapsone, appropriate 
Aldehydes and was evaluated against Mycobacterium Tuberculosis. Compound 3-{2-furyl[4-
(4-{2-furyl [5-(2-naphthyloxymethyl)-2-thioxo-2,3-dihydro-1,3,4-oxadiazol-3 yl] 
methylamino} phenylsulfonyl) anilino]methyl}-5-(2-naphthyloxymethyl)-2,3-dihydro-1,3,4-
oxadiazole-2-thione from all the synthesized compounds have shown best activity against M. 
Tuberculosis and Isoniazide resistant M. Tuberculosis. 
 
  
 
Fig : 3-{2-furyl[4-(4-{2-furyl[5-(2-naphthyloxymethyl)-2thioxo2,3dihydro1,3,4oxadiazole3yl]methylamino} 
phenylsulfonyl)anilino]methyl}-5-(2-naphthyloxymethyl)-2,3 dihydro-1,3,4-oxadiazole-2-thione 
 
 
Manish Kumar Mishra etal[47]  Synthesized 6 – Methyl – 4 – aryl – 5 - (5- phenyl -1, 3, 4 –
oxadiazol -2- yl) -1, 2, 3, 4-tetrahydropyrimidine-2(1H)-one. Among the derivatives 3e has 
significant effect against Streptococcus pneumonia (+ve) and 3b has significant activity effect 
Escherichia coli(-ve) 
 
 
 
Fig: New 6 - Methyl - 4 - aryl - 5 - (5- phenyl -1, 3, 4 -Oxadiazol -2- yl) -1, 2, 3 
, 4-tetrahydropyrimidine-2(1H)-one 
 
 
M. Shahar Yar etal[48]  Synthesized a series of novel 2,5-disubstituted 1,3,4-
oxadiazolederivatives and was tested for invitro Anti-Microbial activity. 2-(2 
naphthyloxymethyl)-5-phenoxymethyl-1, 3, 4-oxadiazole exhibited > 90% inhibition among 
all the synthesized compounds. 
 
                                    Fig: 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives 
 
Mojahidul Islam etal[49]  Synthesized a series of 5-{3’-oxo-6’-(substituted aryl)-2’, 3’, 4’, 
5’-tetrahydropyridazin-2i-ylmethyl}-2-substituted 1, 3, 4-oxadiazole and then final 
compounds were tested for their Anti- bacterial activity using cup plate method. Out of all the 
synthesized compounds 2e and 4 found to be most potent derivative as compared to the 
standard drug. 
 
                       
Fig: 5-{3’-oxo-6’-(substituted aryl)-2’, 3’, 4’, 5’- tetrahydropyridazin-2i-ylmethyl}-2-substituted 1, 3, 
4oxadiazole 
 
 Nitin Bhardwaj  etal[50].  Synthesized 1,3,4-oxadiazole from different compounds and were 
tested for Anti- Microbial activity on different strains. A total of four compounds were 
 
 
synthesized out of those only three found to be effective against bacterial strains and none of 
the strains were found to be effective against fungal strain. 
 
  
 
Yan Li etal[51] Synthesized fifteen novel (E)-a-(methoxyimino)-benzeneacetate 
derivatives.Bioassays indicated that compound 1a-1o showed potent fungicidal activity 
against Rhizoctoniasolani, Botrytis cinereapers, Gibberella zeae, Physalospora piricola and 
Bipolaris mayclis and 1a-1o showed potent fungicidal activity. 
 
         Fig:  (E)-methyl 2-(methoxyimino)-2-(2-((5-phenyl-1, 3, 4-oxadiazol-2-ylthio) methyl)phenyl)acetate 
 
Bao-An Song etal[52] Synthesized compounds using the key intermediates 5-(3,4,5-
trimethoxyphenyl)-1,3,4-thiadiazole-2-thiol or the oxadiazole analogue and tested for 
Fungicidal activity. From all the synthesized compounds 10i and 10j can inhibit mycelium 
growth by approximately 50% in vitro against ten kinds of Fungus 
.  
  
 
 
 
 
Fig:  2-(methylsulfonyl)-5-(3, 4, 5-trimethoxyphenyl)-1,3,4-oxadiazole derivatives 
 
Wildersmith AE etal[53]  Synthesized and found Tuberculostatic and Leprostatic properties 
in a series of 5-(4-pyridyl)-1, 3, 4- oxadiazole-2-thione, and 5-(4-pyridyl)-1,3,4-oxadiazole-2-
one were tested for their Anti TB activity against Mycobacterium and found that all 
synthesized compound were active. 
  
             Fig:  5-(4-pyridyl)-1, 3, 4- oxadiazole-2-thione, 5-(4-pyridyl)-1, 3, 4-oxadiazole-2-one derivatives 
 
Mir I etal[54]  synthesized alpha [5-(2-furyl)-1,3,4-oxadiazol-2-yl-thio] acetohydrazine and 
tested for their activity.  All compounds showed in vitro activity against Mycobacterium 
tuberculosis.  
  
                 Fig: alpha [5-(2-furyl)-1, 3, 4-oxadiazol-2-yl-thio] acetohydrazine derivatives 
 
Kapoor etal[55] Synthesized5-aryl-2- [N-(5-nitrofurfurylidene)] and 5-aryl-2-(N-
thiocarbomylamino)-1,3,4-oxadiazole derivatives and tested for Antimicrobial activity all 
compound reported in were active. 
  
                                            
 
Fig: aryl-2- [N-(5-nitrofurfurylidene)] and 5-aryl-2-(N-thiocarbomylamino)-1, 3, 4-oxadiazole 
 
 
 
 
 
Oxadiazole  as Antibacterial 
 
Nilesh H. Patel  etal[56] synthesised in vitro antibacterial activity of new oxoethylthio-1,3,4-
oxadiazole derivatives. Newly synthesized compounds were tested for their in vitro anti-
tubercular activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460  
radiometric system 
 
 
 
Oxadiazole as Antifungal 
 
Bao-An Song etal[57] synthesized antifungal activities of  5-(3,4,5-trimethoxyphenyl)-2-
sulfonyl-1,3,4-oxadiazole derivatives. The compounds have been shown to be fungicidally 
active. Title compounds 10i and 10j can inhibit mycelia growth by approximately 50% 
(EC50) at 2.9–93.3 lg/mL in vitro against fungi. 
 
  
 
Thiadiazole as  Antitumour 
  
Xin Jian Song  etal[58] synthesized some novel fluorinated pyrazolo[3,4-d]pyrimidine 
derivatives containing 1,3,4-thiadiazole as potential antitumor agents. 
 
 
 
 
 
 
 
Kai Bo  Zheng   etal[59]  synthesized of N1-acetylamino-(5-alkyl/aryl-1,3,4-thiadiazole-2-yl)-
5-fluorouracil derivatives were designed and synthesized. The results of antitumor inhibitory 
activity test showed that some compounds possess more potent antitumor inhibitory activity 
than 5-fluorouracil. 
 
 
 
 
Andanappa.k.Gadad etal[60] synthesized anticancer evaluation of novel 2-
cyclopropylimidazo[2,1-b] [1,3,4]-thiadiazole derivatives. the compounds tested, 5-bromo-6-
(4-chlorophenyl)-2-cyclopropylimidazo[2,1-b][1,3,4]thiadiazole 5b  was found to be the 
most active candidate of the series at five dose level screening with degree of selectivity   
toward Leukemic cancer cell line. 
 
  
Where R=5b=4-Cl 
Thiadiazole as Antidepressant 
 
Mohammad Yusuf, etal[61] synthesized anti-depressant activity of 5-amino-1, 3, 4-
thiadiazole-2-thiol imines and thiobenzyl derivatives. 5-{[1-(4-chlorophenyl)-3-(4-methoxy-
phenyl)prop-2-en-1-ylidene]-amino}- 5-benzylthio-1, 3,4 –thiadiazole 4i(b) and 5-{[1-(4-
chlorophenyl)-3-(4-dimethyl-aminophenyl)-prop-2-en-1-ylidene]amino}-5- benzylthio-1,3,4-
thiadiazole 4i(c) have shown significant anti-depressant activity, All the compounds in the 
series have passed neurotoxicity tests. 
 
 
 
   
 
 
 
 
 
Nadia Salih etal [62] have been reported antimicrobial screening of tetra Schiff bases  of 
1,2,4,5-tetra (5-amino-1,3,4-thiadiazole-2-yl)benzene.The synthesized compounds 1,2,4,5-
tetra[5-(4-nitrobenzylideneamino)-1,3,4-thiadiazole- 2yl]benzene was found to be the most 
potent antimicrobial activity. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVE 
  
                 We  report  the  new  synthesis  of 1,3,4-oxadiazoles  comprising 1,3,4- thiadiazole   
derivatives. The  chemistry   and  Pharmacology   of  oxadiazole  and  thiadiazole   have  
been  of   great  interest  because, of  its  various  biological   activities,  so  that   the  
biological   and  pharmacological  activity   of  oxadiazoles  and  thiadiazoles   may  be  taken  
in  to  account  for  synergism. 
                It  is  well  known  that  the  introduction   of  mannich base  in to  an  organic 
molecules  causes  dramatic  changes  in  its  biological profile. Therefore  it  was  thought  
worth  while  to  synthesize  better  kinds  of  drugs  by  incorporating 1,3,4- oxadiazole  and 
1,3,4-thiadiazole  moiety. 
              In search  for  new  bioactive  potent  molecule, it  was  thought  worth  while  to  
incorporate   some  additional  heterocyclic   moieties in the  oxadiazole  and  thiadiazole  
nucleus   and  study  their  biological  and  pharmacological   activity, the  review  of  
literature  reveal  prompted us  to synthesize substituted 1,3,4-oxadiazole and 1,3,4-
thiadiazole  compounds  and those  will  be  screened  for  antimicrobial, anti-inflammatory, 
anticancer  and  antitubercular  activity   to  get  potent  bioactive  molecule. 
   
.      
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLAN OF WORK 
 
1. Synthesis of 1, 3, 4- oxadiazole  and 1,3,4-thiadiazole  derivatives 
   
Step-I:Synthesis  of semicarbazone  and  thiosemicarbazone 
Synthesis  of titled compound was started from substituted aromatic aldehyde, which upon 
reaction with semicarbazides and thiosemicarbazide  in alcohol to form semicarbazone and 
thiosemicarbazone respectively. 
Step-II :Synthesis  of 2-amino5-substituted 1,3,4-oxadiazole  and 1,3,4-thiadiazole 
Semicarbazone  and  thiosemicarbazone was suspended in   warm water; ferric chloride  in   
warm water was added quantitatively, slowly with constant stirring. The contents were heated 
at 100°C for 2hrs. Solution was filtered and citric acid , sodium carbonate  were added. The 
obtained mixture was divided in to four portions and each portion was neutralized with 
ammonia respectively. The precipitate obtained was recrystallized from alcohol.                          
Step-III:Synthesis  of Mannich base 
The  2-amino-5-substituted-1, 3, 4-oxadiazole  and  2-amino-5-substituted-1,3,4-thiadiazole  
were undergoes mannich reaction with substituted aniline and formaldehyde to get mannich 
base 2-amino 5-substituted 1, 3, 4- oxadiazole and 2-amino 5-substituted 1, 3, 4-  thiadiazole 
derivatives respectively. 
2. Characterization 
The synthesized compounds were characterized by UV, IR, NMR, and Mass 
spectrum. 
 
3. Biological activity 
The synthesized compound will be evaluated for biological activity such as 
a. Antibacterial 
b. Antifungal 
c. Anticancer 
d. Antitubercular 
 
 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental work 
  
Synthetic Work 
Scheme-I 
Synthesis of   1,3,4- Oxadiazole  derivatives 
 
R-CHO +
H2N
N
H
C
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R
fe+++
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Scheme-II 
Synthesis of   1, 3, 4 -Thiadiazole  derivatives 
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I. Synthesis  of 1,3,4-oxadiazole  derivatives 
  
Step-I: Synthesis of  semicarbazone 
  
Synthesis of titled compound was started from substituted aromatic aldehyde, which upon 
reaction with semicarbazides in alcohol to form semicarbazone.. 
R-CHO + NH2 N
H
C
O
NH2
-H2O
Ethanol
R-CH=N-NH-CO-NH2
(Substituted aldehyde) (semicarbazide) (semicarbazone)  
 
Step-II: Synthesis  of 2-amino 5-substituted 1,3,4- oxadiazole 
                           
Semicarbazone (0.01M) was suspended in 300ml of warm water; ferric chloride (0.01M) in 
300ml of warm water was added quantitatively, slowly with constant stirring. The contents 
were heated at 100°C for 2hrs. Solution was filtered and citric acid (0.11M), sodium 
carbonate (0.05M) were added. The obtained mixture was divided in to four portions and 
each portion was neutralized with ammonia. The precipitate obtained was recrystallized from 
alcohol.  
 
R-CH=N-NH-CO-NH2
N N
OR
NH2
Semicarbazone
Na2CO3 and Citricacid
2-amino5-substituted
1,3,4-oxadiazole  
Step-III: Synthesis of  mannich base 
The 2-amino-5-substituted-1, 3, 4-oxadiazole were undergoes mannich reaction with 
substituted aniline and formaldehyde to get mannich base 2-amino 5-substituted 1,3,4- 
oxadiazole derivatives. 
NN
O
R
NH2
+ HCHO  +H2N R1
N
N
O
R
HN CH2
HN R1
Mannich reaction, DMF
 
 
 
 
I Synthesis  of 1,3,4-thiadiazole  derivatives 
Synthesis of titled compound was started from substituted aromatic aldehyde, which upon 
reaction with thiosemicarbazides in alcohol to form thiosemicarbazone. 
  
Step-I: Synthesis of  thiosemicarbazone 
 
R-CHO + NH2 N
H
C
S
NH2
-H2O
Ethanol
R-CH=N-NH-CS-NH2
(Substituted aldehyde) (Thiosemicarbazide) (Thiosemicarbazone)  
 
Step-II: Synthesis  of 2-amino 5-substituted   1,3,4-Thiadiazole 
Thiosemicarbazone (0.01M) was suspended in 300ml of warm water; ferric chlorid 
(0.01M).In 300ml of warm water was added quantitatively, slowly with constant stirring. The 
contents were heated at 100°C for 2hrs. Solution was filtered and citric acid (0.11M), 
sodiumcarbonate (0.05M)  were added. The obtained mixture was divided in to four portions  
and eachportion was neutralized   with ammonia. The precipitate obtained was   recrystallized  
from alcohol 
                         
R-CH=N-NH-CS-NH2 N N
SR
NH2
Thiosemicarbazone
Na2CO3 and Citricacid
2-amino5-substituted
1,3,4-thiadiazole  
 
Step-III: Synthesis of  Mannich base 
The 2-amino-5-substituted1,3,4-thiadiazole were undergoes mannich reaction with 
substituted aniline and formaldehyde to get mannich base 2-amino5-substituted1,3,4-
thiadiazole derivatives. 
NN
S
R
NH2
+ HCHO  +H2N R1
N
N
S
R
HN CH2
HN R1
Mannich reaction, DMF
 
 
 
 
 
 
 
 
II. Characterization 
Characterization of the synthesized compounds by the analytical technique like  
 Thin layer chromatography 
 
 Infrared spectral analysis 
 
 Nuclear magnetic resonance spectral analysis 
 
 Mass Spectroscopy 
 
III.Biological Activity 
Screening of the synthesized compounds for antibacterial , antifungal activity,   anticancer 
and  antitubercular activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
Procedure  for  the  synthesis  of  individual  compound 
 
Synthesis  of  compound  1B 
 
Step-I 
H2N
N
H
C
NH2
O
(semicarbazide)
Water+OHC
(Benzaldehyde)
CH N NH CO NH2
(1-benzylidenesemicarbazide)
EtOH
 
StepII
N N
O NH2
CH N NH CO NH2
1-benzylidenesemicarbazide 5-phenyl-1,3,4-oxadiazol-2-amine
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
 
 
Step-III 
N N
O NH2
5-phenyl-1,3,4-oxadiazol-2-amine
NH2
HCHO, DMF,reflux-4hrs
O2N
N N
O
H
N
H
N
NO2
N-((4-nitrophenylamino)methyl)-5-phenyl-1,3,4-oxadiazol-2-amine4-nitroaniline
 
Procedure 
               To 0.01mole(0.75gm)  of  semicarbazide  in 10ml of water added 0.01 mole 
(1.06gm) of  benzaldehyde  in  10ml  of  ethanol and stirred well for 10mts, the precipitated 
1-benzylidene semicarbazide was filtered and dried. To 0.05 mole (8.15gm)  of 1-
benzylidene semicarbazide  in  300ml  warm water, 0.01 mole (1.62gm) of ferric chloride in  
300ml  water was  added  slowly  with stirring .The contents  were refluxed  for 2hrs at  
1000C. The  solution was filtered  hot and added 0.1mole (19.2gm) of  citricacid and 0.05 
mole (5.25gm) of sodium carbonate.The resulting mixture was neutralised with four portions 
 
 
of ammonia. The  precipitated 5-phenyl1,3,4-oxadiazol-2amine  was  seperated   by 
filteration and recrystallised from ethanol.  
                           To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of   formaldehyde (37-48%)   and 0.02 mole (2.76gm) of 4-
nitroaniline, drop   by drop  with stirring.   
                       The   resulting   mixture   was stirred well and   refluxed   for   4-5hrs,  poured   
in  to the   cold water. The   precipitated 0.025mole (7.16gm) of N-((4-
Nitrophenylamino)methyl)-5-phenyl-1,3,4-oxadiazol-2-amine  was  filtered and dried.The 
product obtained was  recrystallised from ethanol. 
 
Synthesis  of  compound  1E:4-({((5-phenyl-1,3,4-oxadiazol-2-
yl)amino]methyl}amino)benzene  sulphonamide 
 
Step-I 
 
H2N
N
H
C
NH2
O
semicarbazide
+OHC
Benzaldehyde
CH N NH CO NH2
1-benzylidenesemicarbazide
Water
EtOH
 
Step-II 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
N N
O NH2
CH N NH CO NH2
1-benzylidenesemicarbazide 5-phenyl-1,3,4-oxadiazol-2-amine
 
Step-III 
 
N N
O NH2
5-phenyl-1,3,4-oxadiazol-2-amine
NH2
HCHO, DMF,Reflux-4hrs
H2NO2S
NN
ON
H
N
H
H2NO2S
4-({[(5-phenyl-1,3,4-oxadiazol-2-yl)amino]methyl}amino)benzenesulfonamidesulphanilamide
 
 
 
 
Procedure 
                 Dissolve 0.01mole(0.75gm) of  semicarbazide  in 10ml of  warm water added 0.01 
mole(1.06gm) of  benzaldehyde   in     10ml  of  ethanol and stirred well for 10mts, the 
precipitated 1-benzylidene semicarbazide was filtered and dried.To 0.05 mole (8.15gm) of  1-
benzylidene semicarbazide  in  300ml  warmwater, 0.01mole(1.62gm)  of Ferric chloride in  
300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 2hrs at  
1000C. The  solution was filtered  hot and added  0.1 mole (19.2gm) of  citricacid  with 
0.05mole (5.25gm) of sodiumcarbonate. The resulting mixture was neutralised with four 
portions of ammonia. The  precipitated 5-phenyl1,3,4-oxadiazol-2amine was   seperated  by 
filteration and recrystallised from ethanol.    
                           To the above  synthesized compound(0.03mole) added 15ml  of DMF 
followed  by added  1ml of   formaldehyde (37-48%)   and 0.02 mole (3.44gm) of 
sulphanilamide drop   by drop  with stirring. 
                       The   resulting   mixture   was stirred well and   refluxed   for   4-5hrs,  poured   
intocoldwater.Theprecipitated0.025mole(7.45gm)of4({[(5phenyl1,3,4oxadiazolyl)amino]met
hyl}amino)benzene sulphonamide    was  filtered and dried.  The product obtained was  
recrystallised from ethanol. 
Synthesis  of  compound  2B:N-((4-nitrophenylamino)methyl)-5-phenyl-1,3,4-oxadiazol-
2-amine 
   
Step-I  
H2N
N
H
C
NH2
O
semicarbazide
+OHC
P-hydroxybenzaldehyde
CH N NH CO NH2
OH
HO 1-(4-hydroxybenzylidene)semicarbazide
Water
EtOH
 
Step-II 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
CH N NH CO NH2
HO
1-(4-hydroxybenzylidene)semicarbazide
N N
O NH2
HO
4-(5-amino-1,3,4-oxadiazol-2-yl)phenol
 
 
 
 
 
Step-III 
NN
ON
H
N
H
OH
O2N
4-(5-((4-nitrophenylamino)methylamino)-1,3,4-oxadiazol-2-yl)phenol
+ NH2
HCHO, DMF,Reflux 4hrs
O2N
4-nitroaniline
N N
O NH2
HO
4-(5-amino-1,3,4-oxadiazol-2-yl)phenol
 
Procedure 
 Dissolve 0.01mole (0.75gm) of  semicarbazide  in 10ml of  warm water and 0.01 mole 
(1.22gm)of  P-hydroxybenzaldehyde    in  10ml  of  ethanol and stirred well for 10mts, the 
precipitated1-(4-hydroxybenzylidene)semicarbazide was filtered and dried. To 0.005 
mole(0.89gm)  of  1--(4-hydroxybenzylidene ) semicarbazide  in  300ml  warmwater, 
0.01mole (1.62gm)  of ferric chloride in  300ml  water was  added  slowly  with stirring.The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.21gm)  of  citricacid  with 0.05mole  (5.25gm)  of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia. The  precipitated   4-(5-amino-1,3,4-
oxadiazol-2-yl) phenol  was   seperated  by filteration and recrystallised from ethanol. 
                           To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of   formaldehyde (37-48%)   and 0.02 mole (2.76gm) of p-
nitroaniline drop   by drop  with stirring.                       
                           The resulting mixture was stirred well and refluxed for 4-5hrs, poured     
tocoldwater.Theprecipitated0.025mole(7.86gm)of4(5(4nitrophenylamino]methyl}amino)1,3,
4oxadiazol-2-yl)phenol was  filtered and dried.  The product obtained was  recrystallised 
from ethanol.  
       
Synthesis  of  compound  2C:N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-
1,3,4-oxadiazol-2-amine   
Step-I  
+Cl CHO
Parachlorobenzaldehyde
H2N
N
H
C
NH2
O
CH N NH CO NH2
Cl
1-(4-chlorobenzylidene)semicarbazide
Water
EtOH
 
 
 
Step-II 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
N N
O NH2
ClCH N NH CO NH2
Cl
1-(4-chlorobenzylidene)semicarbazide 4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
 
Step-III 
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
NH2
HCHO, DMF,Reflux 4hrs
H3CO
4-methoxyaniline
N N
O
H
N
H
N
OCH3
N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazol-2-amine
Cl
 
Procedure 
                 Dissolve 0.01mole  (0.75gm)of  semicarbazide  in 10ml of  warm water and 0.01 
mole (1.40gm)of P-chlorobenzaldehyde in 10ml of ethanol and stirred well for 10mts, the 
precipitated 1-(4-chlorobenzylidene)semicarbazide was filtered and dried.To 0.5 
mole(0.98gm) of  1-(4-chlorobenzylidene)semicarbazide   in  300ml  warmwater, 
0.01mole(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring.The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole(5.25gm)    of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia. The  precipitated   4-(5-amino-1,3,4-
oxadiazol-2-yl) chloro phenol   was   seperated  by filteration and recrystallised from ethanol.  
           To the above  synthesized compound(0.03mole) added 15ml of  DMF followed by 
added  1ml of   formaldehyde (37-48%)   and 0.02 mole (2.46gm) of p-methoxyaniline drop   
by drop  with stirring. 
       The   reaction   mixture   was stirred well and  refluxed   for   4-5hrs   and   poured   in  to 
the cold water. The precipitated 0.025mol(7.86gm)  of N-((4-methoxyphenylamino]methyl)-
5-(4-Chlorophenyl)- 1,3,4-oxadiazol-2-amine was filtered and dried.  The product obtained 
was  recrystallised  from ethanol.  
 
 
       
 
 
 
Synthesis  of  compound  3B:N-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-N1-(4-
nitrophenyl)methanediamine 
 
Step-I 
+Cl CHO
Parachlorobenzaldehyde
H2N
N
H
C
NH2
O
semicarbazide
CH N NH CO NH2
Cl
1-(4-chlorobenzylidene)semicarbazide
Water
EtOH
 
Step-II 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
N N
O NH2
ClCH N NH CO NH2
Cl
1-(4-chlorobenzylidene)semicarbazide 4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
 
Step-III 
. 
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
NH2
HCHO,DMF,Reflux 4hrs
O2N N
N
O
H
N
H
N
NO2
Cl
-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N
4-nitroaniline
 
Procedure 
                 Dissolve 0.01mole  (0.75gm)of  semicarbazide  in 10ml of  warm water added 0.01 
mole(1.22gm) of  P-hydroxybenzaldehyde    in   10ml  of  ethanol and stirred well for 10mts, 
the precipitated 1-(4-chlorobenzylidene)semicarbazide was filtered and dried.To 
0.5mole(0.98gm) of 1-(4-chlorobenzylidene)semicarbazide in  300ml  warmwater, 
0.01mole(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole(5.25gm)  of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia. The   precipitated   4-(5-amino-
 
 
1,3,4- oxadiazol-2-yl)chlorophenol  was   seperated  by filteration and recrystallised from 
ethanol. 
                             To the above synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of   formaldehyde (37-48%)   and 0.02 mole (2.76gm) of p-
nitroaniline drop   by drop  with stirring. 
                        The   reaction   mixture   was stirred well and   refluxed   for   4-5hrs   and   
poured   in  to the   cold water. The precipitate 0.025mole (8.7gm) of N-(5-(4-Chlorophenyl)-
1,3,4-oxadiazol-2-yl]-N1–(4-nitrophenyl)methanediamine  was filtered and dried.  The 
product obtained was  recrystallised from ethanol. 
 
Synthesis  of  compound  3C:N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-
1,3,4-oxadiazol-2-amine 
  
Step-I 
+Cl CHO
Parachlorobenzaldehyde
H2N
N
H
C
NH2
O CH N NH CO NH2
Cl
1-(4-chlorobenzylidene)semicarbazide
Water
EtOH
 
 
Step-II 
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2yl)chlorophenol
CH N NH CO NH2
Cl 1-(4-chlorobenzylidene)semicarbazide
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
 
 
Step-III 
 
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
NH2
HCHO, DMF,Reflux 4hrs
H3CO
4-methoxyaniline
N N
O
H
N
H
N
Cl
OCH3
N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazol-2-amine
 
 
 
 
 
 
  Procedure 
             Dissolve 0.01mole  (0.75gm) of  semicarbazide  in 10ml of  warm water added 0.01 
mole(1.40gm) of  P-chlorobenzaldehyde    in     10ml  of  ethanol and stirred well for 10mts, 
the precipitated 1-(4-chlorobenzylidene)semicarbazide was   seperated  by filteration.To 
0.005mole (0.98gm)1-(4-chlorobenzylidene)semicarbazide in  300ml  warmwater, 0.01mole 
(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The contents   
were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole  (5.25gm)  of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia. The  precipitated  4-(5-amino-1,3,4-
oxadiazol-2-yl)chlorophenol  was   seperated  by filteration and recrystallised from ethanol. 
           To the above  synthesized compound(0.03mole) added 15ml of  DMF followed by 
added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.46gm) of p-methoxyaniline drop   
by drop  with stirring. 
      The   reaction   mixture   was stirred well and  refluxed   for   4-5hrs   and   poured   in   to 
the coldwater.The precipitate 0.025mole(8.50gm) of N((4Methoxyphenylamino)methyl) 
5(4chlorophyl-1,3,4-oxadiazol-2-yl)chlorophenol    was filtered and dried.  The product 
obtained was  recrystallised from ethanol. 
 
Synthesis of compound 3D:N-(4-Chlorophenyl)-N1-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-
2-yl]methanediamine 
Step-I 
+Cl CHO
Parachlorobenzaldehyde
H2N
N
H
C
NH2
O
(semicarbazide
CH N NH CO NH2
Cl 1-(4-chlorobenzylidene)semicarbazide
Water
EtOH
 
Step-II 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
CH N NH CO NH2
Cl 1-(4-chlorobenzylidene)semicarbazide
 
 
 
 
Step-III 
HCHO, DMF,Reflux 4hrs
N N
O NH2
Cl
4-(5-amino-1,3,4-oxadiazol-2-yl)chlorophenol
NH2Cl
N N
O
H
N
H
N
Cl
Cl
-(4-chlorophenyl)- '-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methanediamN N
4-chloroaniline
 
Procedure 
 
                 Dissolve 0.01mole  (0.75gm)of  semicarbazide  in 10ml of  warm water and 0.01 
mole (1.40gm)of  P-chlorobenzaldehyde in 10ml  of  ethanol and stirred well for 10mts, the 
precipitated 1-(4-chlorobenzylidene)semicarbazide was     filtered and  dried. To   0.005mole 
(0.98gm) of 1-(4-chlorobenzylidene)semicarbazide in 300ml  warm water, 0.01mole(1.62gm)  
of Ferric chloride in  300ml  water was  added  slowly  with stirring. The contents   were  
refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  
citricacid  with 0.05mole (5.25gm) of sodiumcarbonate. The resulting mixture was 
neutralised with four portions of ammonia. The  precipitated  4-(5-amino-1,3,4-oxadiazol-2-
yl)chlorophenol  was   seperated  by filteration and recrystallised from ethanol.  
               To the above  synthesized compound(0.03mole) added 15ml of  DMF followed by 
added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.55gm) of p-Chloroaniline drop   by 
drop  with stirring. 
                  The   reaction   mixture   was  stirred well and    refluxed   for   4-5hrs   and   
poured   in   to the   cold water. The precipitate 0.025mole(9.16gm) of N-((4-
Chlorophenyl)N1-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methanediamine was filtered and 
dried.The product obtained was  recrystallised from ethanol. 
 
 
 
  
 
 
Synthesis  of  compound  4B:N-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-N1-(4-
nitrophenyl)methanediamine 
Step-I 
 
+CHO
2-chlorobenzaldehyde
H2N
N
H
C
NH2
O
semicarbazide
CH N NH CO NH2
1-(2-chlorobenzylidene)semicarbazide
Cl
Cl
Water
EtOH
 
Step-II 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs N N
O NH2
Cl
5-(2-chlorophenyl)-1,3,4-oxadiazol-2-amine
CH N NH CO NH2
1-(2-chlorobenzylidene)semicarbazide
Cl
 
 
Step-III 
 
N N
O NH2
Cl
(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-amine))
NH2
(nitroaniline)
HCHO,DMF,reflux-4hrs
O2N
N N
O
H
N
H
N
Cl
NO2
-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N
 
Procedure 
                          Dissolve 0.01mole  (0.75gm) of  semicarbazide  in 10ml of  warm  water 
added 0.01 mole of  2-chlorobenzaldehyde    in     10ml  of  ethanol and stirred well for 
10mts, the precipitated 1-(2-chlorobenzylidene)semicarbazide was filtered and dried.To 
0.005 mole(0.96gm) of 1-(2-chlorobenzylidene)semicarbazide in  300ml  warm water, 
0.01mole(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole(5.25gm)  of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia. The  precipitated (5-(2-
 
 
chlorophenyl)- 1,3,4-oxadiazol-2-amine   was   seperated  by filteration and recrystallised 
from ethanol.                         
                   To the above  synthesized compound(0.03mole) added 15ml of  DMF followed 
by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.76gm) of p-nitroaniline drop  by 
drop  with stirring.                                                  
                  The   reaction   mixture   was  stirred well  and  refluxed   for   4-5hrs   and   
poured   in   to the   cold  water. The  precipitate 0.025mole  (7.89gm) of  N[5chlorophenyl)-
1,3,4-oxadiazol-2-yl]-N(4nitrophenyl)methanediamine  was  filtered and dried. The product 
obtained was  recrystallised from ethanol.   
 
Synthesis  of  compound  4E:4-[({[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-
yl]amino}methyl)amino]benzenesulphonamide 
  
Step-I 
+CHO
2-chlorobenzaldehyde
H2N
N
H
C
NH2
O
semicarbazide
CH N NH CO NH2
1-(2-chlorobenzylidene)semicarbazide
Cl
Cl
Water
EtOH
 
 
Step-II 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs N N
O NH2
Cl
5-(2-chlorophenyl)-1,3,4-oxadiazol-2-amine
CH N NH CO NH2
1-(2-chlorobenzylidene)semicarbazide
Cl
 
Step-III 
 
N N
O NH2
Cl
5-(2-chlorophenyl)-1,3,4-oxadiazol-2-amine
NH2
HCHO,DMF,reflux-4hrs
H2NO2S
Sulphanilamide
N N
O
H
N
H
N
Cl
SO2NH2
4-[({[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonami
 
 
 
Procedure 
                                  Dissolve 0.01mole (0.75gm) of  semicarbazide  in 10ml of  warm  water 
added 0.01 mole of  2-chlorobenzaldehyde    in     10ml  of  ethanol and stirred well for 
10mts, the precipitated 1-(2-chlorobenzylidene)semicarbazide was filtered and dried.To 
0.005 mole(0.96gm)  of 1-(2-chlorobenzylidene)semicarbazide in 300ml  warm water, 
0.01mole(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of ammonia. The  precipitated (5-(2-
chlorophenyl)- 1,3,4-oxadiazol-2-amine   was   seperated  by filteration and recrystallised 
from ethanol.                         
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.44gm) of p-
sulphanilamide drop   by drop  with stirring. 
                         The   reaction   mixture   was stirred well and  refluxed   for   4-5hrs   and   
poured   in   to the coldwater. The precipitate 0.025mole(7.8gm)  4-[({[5-(2-Chlorophenyl)-
1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzene sulphonamide  was filtered and dried.  
The product obtained was  recrystallised from ethanol.        
Synthesis  of  compound  5E: N-(4-Sulphonamyl)-N-[5-(3-Fluorophenyl)-1,3,4-
oxadiazol-2-yl]methanediamine 
 
CHO
CH N NH CO NH2
H2N
N
H
C
NH2
O
+
Step1
semicarbazide
I
F F
3-Fluorobenzaldehyde 1-(3-fluorobenzylidene)semicarbazide
Water
EtOH
  
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
5-(3-fluorophenyl)-1,3,4-oxadiazol-2-amine
N N
O NH2
F
CH N NH CO NH2
Step1II
F
1-(3-fluorobenzylidene)semicarbazide
 
 
 
 
Step-III 
N N
O
H
N
H
N
F
SO2NH2
N-(4-Sulphonamyl)-N-[5-(3-Fluorophenyl)-1,3,4-oxadiazol-2-yl]methanediamine
NH2
HCHO,DMF,Reflux 4hrs
H2NO2S
Sulphanilamide
5-(3-fluorophenyl)-1,3,4-oxadiazol-2-amine
N N
O NH2
F
 
Procedure 
.  
           Dissolve 0.01mole  (0.75gm) of  semicarbazide  in 10ml of  warm  water added 0.01 
mole of  3-Flurobenzaldehyde    in     10ml  of  ethanol and stirred well for 10mts, the 
precipitated   1-(3-fluorobenzylidene)semicarbazide was filtered and dried.    To 0.005 mole 
(0.90gm) of 1-(3-fluorobenzylidene)semicarbazide in  300ml  warm water, 0.01mole 
(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The contents   
were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of ammonia. The  precipitate(5-(3-fluorophenyl)- 
1,3,4-oxadiazol-2-amine)   was   seperated  by filteration and recrystallised from ethanol.                         
                         To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.44gm) of p-
Sulphanilamide drop   by drop  with stirring. 
                        The   reaction   mixture   was stirred well and  refluxed   for   4-5hrs   and   
poured   in   to the coldwater. The precipitate 0.025mole (7.8gm) of N-(4-Sulphonamyl)-N-
[5-(3-Fluorophenyl)-1,3,4-oxadiazol-2-yl]methanediamine was   filtered and dried.  The 
product obtained was  recrystallised from ethanol. 
   
Synthesis  of  compound  6B:N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-
nitrophenylmethanediamine 
  
+CHOO2N
4-nitrobenzaldehyde
Water
CH N NH OC NH2
H2N
N
H
C
NH2
O
(semicarbazide)
Step1I
EtOH
O2N
1-(4-nitrobenzylidene)semicarbazide
 
 
 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
N N
O NH2
O2N
5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine
CH N NH OC NH2
O2N
Step1II
 
N N
O NH2
O2N
5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine
Step1III
N N
O
H
N
H
N
O2N
NO2
N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-nitrophenylmethanediam
NH2
(nitroaniline)
HCHO, DMF,reflux-4hrs
O2N
 
Procedure 
 
Dissolve 0.01mole  (0.75gm) of  semicarbazide  in 10ml of  warm  water added 0.01 mole of  
4-Nitrobenzaldehyde    in     10ml  of  ethanol and stirred well for 10mts, the precipitated   1-
(4-Nitrobenzylidene)semicarbazide was filtered and dried To 0.005 mole (1.04gm)  of 1-(4-
Nitrobenzylidene)semicarbazide in  300ml  warm water, 0.01mole (1.62gm)  of Ferric 
chloride in  300ml  water was  added  slowly  with stirring. The contents  were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  
with 0.05mole(5.25gm)  of sodiumcarbonate. The resulting mixture was neutralised with four 
portions of ammonia. The  precipitated(5-(4-Nitrophenyl)- 1,3,4-oxadiazol-2-amine)   was   
seperated  by filteration and recrystallised from ethanol.                       
                           To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.76gm) of p-nitroaniline 
drop   by drop  with stirring. 
               The   reaction   mixture   was  stirred well and  refluxed   for   4-5hrs   and   poured   
in   to the coldwater. The precipitate 0.025mole(7.75gm) of N-[5-(4-nitrophenyl)-1,3,4-
oxadiazol-2-yl]-N1-nitrophenylmethanediamine was filtered and dried.The product obtained 
was  recrystallised from ethanol. 
 
 
 
 
 
 
 Synthesis of compound 6E:  4-[({[5-(4-nitrophenyl)-1,3,4-oxadiazol-
2yl]amino}methyl)amino]benzenesulphonamide  
 
+CHOO2N
4-nitrobenzaldehyde
Water
CH N NH OC NH2
H2N
N
H
C
NH2
O
semicarbazide
Step1I
EtOH
O2N
1-(4-nitrobenzylidene)semicarbazide
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N N
O NH2
O2N
5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine
CH N NH OC NH2
O2N
1-(4-nitrobenzylidene)semicarbazide
Step1II
 
 
Step1III
N N
O NH2
O2N
5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine
N
N
ON
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonami
NH2
HCHO,DMF,Reflux 4hrs
H2NO2S
Sulphanilamide
 
Procedure 
Dissolve 0.01mole  (0.75gm) of  semicarbazide  in 10ml of  warm  water added 0.01 mole of  
4-Nitrobenzaldehyde    in     10ml  of  ethanol and stirred well for 10mts, the precipitated  1-
(4-Nitrobenzylidene)semicarbazide was filtered and dried.    To 0.005 mole(1.04gm)  of 1-(4-
Nitrobenzylidene)semicarbazide in  300ml  warm water, 0.01mole (1.62gm)   of Ferric 
chloride in  300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole (19.2gm) of  citricacid  
with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting mixture was neutralised 
withfour portions of ammonia. The  precipitate(5-(4-Nitrophenyl)- 1,3,4-oxadiazol-2-amine)   
was   seperated  by filteration and recrystallised from ethanol.                        
 
 
                         To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.44gm) of p-
sulphanilamide drop   by drop  with stirring.  
                         The   reaction   mixture   was stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate 0.025 mole(7.75gm)  of  4-[({[5-(4-
nitrophenyl)-1,3,4-oxadiazol-2yl]amino}methyl)amino]benzenesulphonamide  was filtered 
and dried.  The product obtained was  recrystallised from ethanol. 
          
Synthesis  of  compound 8A1:   4-[({[5-(3-Chlorophenyl)-1,3,4-thiadiazol-2-
yl]amino}methyl)amino]benzenesulphonamide  
 
3-Chlorobenzaldehyde
+
CHO
H2N
N
H
C
NH2
S
Thiosemicarbazide
Step1I
CH N NH C
NH2
S
1-(3-chlorobenzylidene)thiosemicarbazide
ClCl
Water
EtOH
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
S
NN
NH2Cl
5-(3-chlorophenyl)-1,3,4-thiadiazol-2-amine
Step1II
CH N NH C
NH2
Cl
S
1-(3-chlorobenzylidene)thiosemicarbazide
 
S
NN
NH2Cl
5-(3-chlorophenyl)-1,3,4-thiadiazol-2-amine
N N
S
H
N
H
N
Cl SO2NH2
4-[({[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamid
Step1III
NH2
HCHO,DMF,Reflux 4hrs
H2NO2S
Sulphanilamide
 
Procedure 
 
                     Dissolve 0.01mole(0.91gm) of  thio semicarbazide  in 10ml of  warm  water 
added 0.01 mole(1.40gm) of 3-Chlorobenzaldehyde    in   10ml  of  ethanol and stirred well 
 
 
for 10mts, the precipitated  1-(3-Chlorobenzylidene) thiosemicarbazide was filtered and 
dried. To 0.005 mole (1.56gm) of 1-(3-Chlorobenzylidene)thiosemicarbazide in  300ml  
warm water, 0.01mole(1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with 
stirring. The contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and 
added  0.1 mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The 
resulting mixture was neutralised with four portions of ammonia. The  precipitated(5-(3-
Chlorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised 
from ethanol.                         
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.45gm) of p-
sulphanilamide drop   by drop  with stirring. 
                          The   reaction   mixture   was stirred  well  and  refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate  0.025(9.85gm) of 4-[({[5-(3-Chlorophenyl)-
1,3,4-thiadiazol-2yl]amino}methyl)amino]benzenesulphonamide  was filtered and dried.  The 
product obtained was  recrystallised from ethanol. 
                
Synthesis  of  compound 8A2: 
(4-Chlorophenyl)-N1-[5-(3-Chlorophenyl)-1,3,4-thiadiazol-2-yl]methanediamine  
  
3-Chlorobenzaldehyde
+
CHO
H2N
N
H
C
NH2
S
Thiosemicarbazide
Step1I
CH N NH C
NH2
S
1-(3-chlorobenzylidene)thiosemicarbazide
ClCl
Water
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S
NN
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S
NN
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N N
S
H
N
H
N
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Cl
4-chloroaniline
 
Procedure         
                     Dissolve 0.01mole(0.91gm) of  thio semicarbazide  in 10ml of  warm  water 
added 0.01 mole (1.40gm) of 3-Chlorobenzaldehyde    in   10ml  of  ethanol and stirred well 
for 10mts, the precipitated  1-(3-Chlorobenzylidene) thiosemicarbazide was filtered and 
dried.To 0.005mole (1.56gm)  of 1-(3-Chlorobenzylidene)thiosemicarbazide in  300ml  warm 
water, 0.01mole (1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with 
stirring. The contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and 
added  0.1 mole (19.2gm) of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The 
resulting mixture was neutralised with  four portions of ammonia. The  precipitated(5-(3-
Chlorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised 
from ethanol. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.55gm) of p-
Chloroaniline drop   by drop  with stirring. 
                                                  The   reaction   mixture   was .  stirred well and    refluxed   for   
4-5hrs   and   poured   in   to  the coldwater. The  precipitate  0.025 mole(8.95gm) N-(4-
Chlorophenyl)-N-[5-(3-Chlorophenyl)-1,3,4-thiadiazol-2yl]methanediamine  was filtered and 
dried.  The product obtained was  recrystallised from ethanol. 
              
Synthesis  of  compound  8A3:N-[5-(3-Chlorophenyl)-1,3,4-thiadiazol-2-yl]-N1-(4-
nitrophenyl)methanediamine 
3-Chlorobenzaldehyde
+
CHO
H2N
N
H
C
NH2
S
Thiosemicarbazide
Step1I
CH N NH C
NH2
S
1-(3-chlorobenzylidene)thiosemicarbazide
ClCl
Water
EtOH
 
 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
S
NN
NH2Cl
5-(3-chlorophenyl)-1,3,4-thiadiazol-2-amine
Step1II
CH N NH C
NH2
Cl
S
1-(3-chlorobenzylidene)thiosemicarbazide
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Cl
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N N
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N
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N
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-[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N
 
Procedure 
                    Dissolve 0.01mole(0.91gm)  of  thio semicarbazide  in 10ml of  warm  water 
added 0.01 mole(1.40gm)  of 3-Chlorobenzaldehyde    in   10ml  of  ethanol and stirred well 
for 10mts, the precipitated  1-(3-Chlorobenzylidene) thiosemicarbazide was filtered and 
dried. To 0.005mole(1.56gm) of 1(3Chlorobenzylidene)thiosemicarbazide in  300ml  warm 
water, 0.01mole (1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with 
stirring. The contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and 
added  0.1 mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The 
resulting mixture was neutralised with four portions of  ammonia. The  precipitated(5-(3-
Chlorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised 
from ethanol. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.75gm) of p-nitroaniline 
drop   by drop  with stirring.  
                       The   reaction   mixture   was      stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate 0.025mole(8.45gm) of  N-[5-(3-
Chlorophenyl)-1,3,4-thiadiazol-2yl] N-(4-Nitrophenyl)-methanediamine  was filtered and 
dried.  The product obtained was  recrystallised from ethanol. 
 
 
              
 
 
Synthesis  of  compound8B1: 
 4-[({[5-(2-Chlorophenyl)-1,3,4-thiadiazolyl]amino}methyl)amino]benzenesulphonamide  
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+
CHO
H2N
N
H
C
NH2
S
Thiosemicarbazide
Step1I
CH N NH C
NH2
S
1-(2-chlorobenzylidene)thiosemicarbazide
Cl
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Procedure 
                                Dissolve 0.01mole(0.91gm)  of  thio semicarbazide  in 10ml of  warm  
water added 0.01 mole(1.40gm) of 2-Chlorobenzaldehyde   in  10ml  of  ethanol and stirred 
well for 10mts, the precipitated  1-(2-Chlorobenzylidene)thiosemicarbazide was filtered and 
dried To 0.005 mole(0.106gm)  of 1-(2-Chlorobenzylidene)thiosemicarbazide in  300ml  
warm water, 0.01mole (1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with 
stirring. The contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and 
added  0.1 mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The 
resulting mixture was neutralised with four portions of  ammonia. The  precipitate(5-(2-
Chlorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised 
from ethanol. 
 
 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.45gm) of p-
sulphanilamide drop   by drop  with stirring. 
                         The   reaction   mixture   was stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate  0.025mole (8.95gm) of 4-[({[5-(2-
Chlorophenyl)-1,3,4-thiadiazol-2yl]amino}methyl}amino  benzene sulphonamide  was 
filtered and dried.  The product obtained was  recrystallised from ethanol.    
Synthesis  of  compound8B2: 
 N-(4-Chlorophenyl)-N1-[5-(2-Chlorophenyl)-1,3,4-thiadiazol-2-yl]methanediamine 
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Procedure 
                   Dissolve 0.01mole(0.91gm)  of  thio semicarbazide  in 10ml of  warm  water and 
0.01 mole(1.40gm) of 2-Chlorobenzaldehyde in 10ml  of  ethanol and stirred well for 10mts, 
the precipitated to form  1-(2-Chlorobenzylidene) thiosemicarbazid was filtered and dried .To 
 
 
0.005mole(0.106gm)  of 1 -(2-Chlorobenzylidene)thiosemicarbazide in  300ml  warm water, 
0.01mole (1.62gm)  of  Ferric chloride in  300ml  water was  added  slowly  with stirring. The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole (19.2gm) of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of ammonia. The  precipitate(5-(2-Chlorophenyl)- 
1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised from ethanol. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.55gm) of p-
Chloroaniline drop   by drop  with stirring.  
                        The   reaction   mixture   was stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate 0.025mole (8.95gm) of N-[5-(2-
Chlorophenyl)-1,3,4-thiadiazol-2yl] N-(4-Chlorophenyl)-methanediamine  was filtered and 
dried.  The product obtained was  recrystallised from ethanol.  
 
Synthesis  of  compound 8B3 : 
N-[5-(2-Chlorophenyl)-1,3,4-thiadiazol-2-yl]-N1-(4-nitrophenyl)methanediamine  
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S
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Step1I
CH N NH C
NH2
S
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Cl
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S
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Step1II
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-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N
   
Procedure       
                    Dissolve 0.01mole (0.91gm)of  thio semicarbazide  in 10ml of  warm  water added 
0.01 mole(1.40gm) of 2-Chlorobenzaldehyde  in  10ml  of  ethanol and stirred well for 10mts, 
the precipitated  1-(2-Chlorobenzylidene)thiosemicarbazide was filtered and dried. To 0.005 
mole(0.106gm)  of 1-(2-Chlorobenzylidene)thiosemicarbazide in  300ml  warm water, 
0.01mole (1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with stirring. The 
contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and added  0.1 
mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting 
mixture was neutralised with four portions of  ammonia ammonia. The  precipitate(5-(2-
Chlorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration and recrystallised 
from ethanol.  
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.76gm) of p-nitroaniline 
drop   by drop  with stirring. 
                       The   reaction   mixture  was  stirred well and  refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate  0.025mole  of (9.25gm) of N-[5-(2-
Chlorophenyl)-1,3,4-thiadiazol-2yl] N-(4-Nitrophenyl)-methanediamine  was filtered and 
dried.  The product obtained was  recrystallised from ethanol. 
  
Synthesis  of  compound 8C1:4-[({[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-
yl]amino}methyl)amino]benzenesulphonamide  
   
3-Fluorobenzaldehyde
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C
NH2
S
Thiosemicarbazide
Step1I CH N NH C
NH2
S
1-(3-Fluorobenzylidene)thiosemicarbazide
F
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Step1II
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S
NN
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F
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4-[({[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonami
Step1III
NH2
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H2NO2S
Sulphanilamide
 
Procedure 
 
                  Dissolve 0.01mole (0.91gm)of  thio semicarbazide  in 10ml of  warm  water added 
0.01 mole(1.24gm) of 3-fluorobenzaldehyde    in     10ml  of  ethanol  and stirred well for 
10mts, the precipitated  1-(3-Fluorobenzylidene) thiosemicarbazide was filtered and dried.    
To 0.005 mole(0.98gm)  of 1-(3-Fluorobenzylidene)thiosemicarbazide in  300ml  warm 
water, 0.01mole (1.62gm)  of Ferric chloride in  300ml  water was  added  slowly  with 
stirring. The contents   were  refluxed  for 2hrs at  1000C. The  solution was filtered  hot and 
added  0.1 mole(19.2gm)  of  citricacid  with 0.05mole (5.25gm)   of sodiumcarbonate. The 
resulting mixture was neutralised with . four portions of  ammonia. The  precipitate (5-(3-
Fluorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration  and recrystallised 
from ethanol. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.45gm) of p-
sulphanilamide drop   by drop  with stirring. 
                         The reaction mixture was stirred well and refluxed for 4-5hrs and   
pouredintothecoldwater.Theprecipitate0.025mole(9.55gm)of4[({[5(3fluorophenyl)1,3,4thiadi
azol2yl]amino}methyl)amino]benzenesulphonamidewascollected. was filtered and dried.  
The product obtained was  recrystallised from ethanol.  
 
 
Synthesis  of  compound 8C2:  N-(4-Chlorophenyl)-N1-[5-3-fluorophenyl)-1,3,4-
thiadiazol-2-yl]methanediamine 
3-Fluorobenzaldehyde
+
CHO
H2N
N
H
C
NH2
S
Thiosemicarbazide
Step1I CH N NH C
NH2
S
1-(3-Fluorobenzylidene)thiosemicarbazide
F
F
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Step1II
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-(4-chlorophenyl)- '-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N
  
Procedure 
 
                     Dissolve 0.01mole(0.91gm) of  thio semicarbazide  in 10ml of  warm  water and 
0.01 mole91.24gm) of 3-fluorobenzaldehyde    in     10ml  of  ethanol to form  1-(3-
Fluorobenzylidene) thiosemicarbazide. To 0.005 mole(0.98gm)   of 1-(3-
Fluorobenzylidene)thiosemicarbazide in  300ml  warm water, 0.01mole (1.62gm)  of Ferric 
chloride in  300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  
with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting mixture was neutralised with 
ammonia. The  precipitate(5-(3-Fluorophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  
by filteration. ethanol and stirred well for 10mts, the precipitated was filtered and dried. four 
portions of  ammonia. and recrystallised from ethanol. 
 
 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.55gm) of p-
Chloroaniline drop   by drop  with stirring. 
                       The   reaction   mixture  was stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate  0.025mole (8.95gm) of N-(4-Chlorophenyl)-
N1-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]methanediamine was filtered and dried.  The 
product obtained was  recrystallised from ethanol.   
 
Synthesis  of  compound 8D1: 
 4-[({[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-
yl]amino}methyl)amino]benzenesulphonamide 
  
WaterCHOO2N
P-nitrobenzaldehyde
+ H2N
N
H
C
NH2
S
Thiosemicarbazide
StepI
EtOH
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
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StepIII
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Sulphanilamide
NN
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HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
NO2
 
Procedure 
 
                    Dissolve 0.01mole(0.91gm)  of  thio semicarbazide  in 10ml of  warm  water and 
0.01 mole(1.510gm) of 4-nitrobenzaldehyde in  10ml  of  ethanol to form  1-(4-
 
 
nitrobenzylidene) thiosemicarbazide. To 0.005 mole (0.112gm) of 1-(4-
nitrobenzylidene)thiosemicarbazide in  300ml  warm water, 0.01mole(1.62gm)  of  Ferric 
chloride in  300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  
with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting mixture was neutralised with 
ammonia. The  precipitate(5-(4-nitrophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by 
filteration. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (3.45gm) of p-
sulphanilamide drop   by drop  with stirring. 
                          The   reaction mixture  was stirred well and   refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate 0.025 mole(10.5gm) of 4-[({[5-(4-
nitrophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl}amino]benzenesulphonamide was filtered 
and dried.  The product obtained was  recrystallised from ethanol.  
 
Synthesis  of  compound 8D2: 
N-(4-nitrophenyl)-N-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamine   
 
WaterCHOO2N
P-nitrobenzaldehyde
+ H2N
N
H
C
NH2
S
Thiosemicarbazide
StepI
EtOH
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
Step1II NO2
 
 
 
NH2
HCHO, DMF,Reflux 4hrs
O2N
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
NO2
p-nitroaniline
NN
SN
HNH
NO2
O2N
-(4-nitrophenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediaminN N
Step1III
 
Procedure 
 
Dissolve 0.01mole (0.91gm) of  thio semicarbazide  in 10ml of  warm  water and 0.01 
mole(1.51gm) of 4-nitrobenzaldehyde in 10ml  of  ethanol to form  1-(4-
nitrobenzylidene)thiosemicarbazide.To 0.05mole(0.112gm)of  1(4nitrobenzylidene)thio 
semicarbazide in  300ml  warm water, 0.01mole(1.62gm)  of Ferric chloride in  300ml  water 
was  added  slowly  with stirring. The contents   were  refluxed  for 2hrs at  1000C. The  
solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  with 0.05mole(5.25gm)  
of sodiumcarbonate. The resulting mixture was neutralised with ammonia. The  precipitate(5-
(4-nitrophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by filteration. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.76gm) of p-nitroaniline 
drop   by drop  with stirring. 
                         The   reaction   mixture  was  stirred  well and  refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The precipitate  0.025mole (9.754gm) of N-(4-nitrophenyl)-N-
[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamine was filtered and dried.  The product 
obtained was  recrystallised from ethanol.  
 
Synthesis  of  compound 8D3 :  N-(4-Chlorophenyl)-N1-[5-(4-nitrophenyl)-1,3,4-
thiadiazol-2-yl]methanediamine 
 
CHOO2N
P-nitrobenzaldehyde
+ H2N
N
H
C
NH2
S
Thiosemicarbazide
StepI
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
EtOH
Water
 
 
 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
Step1II NO2
 
 
NH2Cl
Parachloroaniline
NN
SN
HNH
NO2
Cl
-(4-chlorophenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediaminN N
HCHO, DMF,Reflux 4hrs
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
NO2
Step1III
 
Procedure 
 
                     Dissolve 0.01mole(0.91gm) of  thio semicarbazide  in 10ml of  warm  water and 
0.01 mole(1.510gm)  of 4-nitrobenzaldehyde    in     10ml  of  ethanol to form  1-(4-
nitrobenzylidene) thiosemicarbazide. To 0.005 mole(0.112gm)   of 1-(4-
nitrobenzylidene)thiosemicarbazide in  300ml  warm water, 0.01mole(1.62gm)  of  Ferric  
chloride in  300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  
with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting mixture was neutralised with 
ammonia. The  precipitate(5-(4-nitrophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by 
filteration. 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.76gm) of p-
chloroaniline drop   by drop  with stirring. 
                                                   The   reaction   mixture   was stirred well and    refluxed   for   
4-5hrs   and   poured   in   to  the coldwater. The  precipitate 0.025mole (9.75gm) of  N-(4-
chlorophenyl)-N-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamine was filtered and 
dried.  The product obtained was  recrystallised from ethanol. 
 
 
 
Synthesis  of  compound  8D4:  N-(4-methoxyphenyl)-N1-[5-(4-nitrophenyl)-1,3,4-
thiadiazol-2-yl]methanediamine 
  
EtOH
Water
CHOO2N
P-nitrobenzaldehyde
+ H2N
N
H
C
NH2
S
Thiosemicarbazide
StepI
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
 
 
Fe,+++ Na2CO3,citricacid
Reflux 2hrs
CH N NH C
NH2
S
NO2
1-(4-nitrobenzylidene)thiosemicarbazide)
S
NN
NH2
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
Step1II NO2
 
 
HCHO, DMF,Reflux 4hrs
Step1III
S
NN
NH2
NH2H3CO
O2N
5-(4-nitrophenyl)-1,3,4-thiadiazol-2-amine
Paramethoxyaniline
N
N
SN
HNH
NO2
H3CO
-(4-methoxyphenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediaminN N
 
 
Procedure 
 Dissolve 0.01mole(0.91gm)  of  thio semicarbazide  in 10ml of  warm  water and 0.01 
mole(1.510gm)  of 4-nitrobenzaldehyde    in     10ml  of  ethanol to form  1-(4-
nitrobenzylidene) thiosemicarbazide. To 0.005 mole(0.112gm)  of 1-(4-
nitrobenzylidene)thiosemicarbazide in  300ml  warm water, 0.01mole (1.62gm)   of Ferric 
chloride in  300ml  water was  added  slowly  with stirring. The contents   were  refluxed  for 
2hrs at  1000C. The  solution was filtered  hot and added  0.1 mole(19.2gm)  of  citricacid  
with 0.05mole (5.25gm)   of sodiumcarbonate. The resulting mixture was neutralised with 
ammonia. The  precipitate(5-(4-nitrophenyl)- 1,3,4-thiadiazol-2-amine)   was   seperated  by 
filteration. 
 
 
                        To the above  synthesized compound(0.03mole) added 15ml of  DMF 
followed by added  1ml of formaldehyde(37-48%)   and 0.02 mole (2.56gm) of p-
methoxyaniline drop   by drop  with stirring. 
                       The   reaction   mixture   was  stirred well and    refluxed   for   4-5hrs   and   
poured   in   to  the coldwater. The  precipitate 0.025mole(9.25gm) of  N-(4-methoxyphenyl)-
N-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamine was  filtered and dried.  The 
product obtained  was  recrystallised  from ethanol. 
   
.  
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF COMPOUNDS 
SYNTHESIZED 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          List  of  compounds  
synthesized 
        Table no:1  
Serial  
no 
Compound 
code 
Structure  of  compounds  and  chemical name 
1 
           
              
 
 
1b 
 
N N
O
H
N
H
N
NO2
N-((4-nitrophenylamino)methyl)-5-phenyl-1,3,4-oxadiazol-2-amine  
2 
 
 
 
1e 
 
 
NN
ON
H
N
H
H2NO2S
4-({[(5-phenyl-1,3,4-oxadiazol-2-yl)amino]methyl}amino)benzenesulfonamide  
3 
 
 
 
2b 
 
 
NN
ON
H
N
H
OH
O2N
4-(5-((4-nitrophenylamino)methylamino)-1,3,4-oxadiazol-2-yl)phenol  
4 
 
 
 
2c 
 
 
NN
ON
H
N
H
OH
H3CO
4-[5-({[(4-methoxyphenyl)amino]methyl}amino)-1,3,4-oxadiazol-2-yl]phenol  
5 
 
 
 
3b 
N N
O
H
N
H
N
NO2
Cl
-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-methylphenyl)methanediamineN N  
 
 
6 
 
 
 
3c 
 
 N N
O
H
N
H
N
Cl
OCH3
N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazol-2-amine  
7 
 
 
 
3d 
N N
O
H
N
H
N
Cl
Cl
-(4-chlorophenyl)- '-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methanediamineN N  
8 
 
 
 
4b 
N N
O
H
N
H
N
Cl
NO2
-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N  
9 
 
 
 
4e 
 
 N N
O
H
N
H
N
Cl
SO2NH2
4-[({[5-(2-chlorophenyl)-1,3,4-oxadiazol-2yl]amino}methyl)amino]benzenesulfonamide  
10 
 
 
5e 
 
 
   
N N
O
H
N
H
N
F SO2NH2
N-(4-Sulphonamyl)-N-[5-(3-Fluorophenyl)-1,3,4-oxadiazol-2-yl]methanediamine  
11 
 
6b 
N N
O
H
N
H
N
O2N
NO2
N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-nitrophenylmethanediamine  
 
 
12 6e NN
ON
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
13 8a1  
N N
S
H
N
H
N
Cl SO2NH2
4-[({[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
14 8a2  
N N
S
H
N
H
N
Cl
Cl
-(4-chlorophenyl)- '-[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
15 8a3 
N N
S
H
N
H
N
Cl NO2
-[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N  
16 8b1 
4-[({[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
NN
SN
H
N
H
Cl
H2NO2S
 
17 8b2 
N N
S
H
N
H
N
Cl
Cl
-(4-chlorophenyl)- '-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
 18 8b3 
N N
S
H
N
H
N
Cl
NO2
-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N  
 
 
 
 
 
 
 
 
19 8c1 
NN
SN
H
N
H
H2NO2S
4-[({[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
F
 
20 8c2 
NN
SN
H
N
H
F
Cl
-(4-chlorophenyl)- '-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
21 8d1 NN
SN
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
22 8d2                                                                                             
NN
SN
HNH
NO2
O2N
-(4-nitrophenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
23 8d3 NN
SN
HNH
NO2
Cl
-(4-chlorophenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
24 8d4 NN
SN
HNH
NO2
H3CO
-(4-methoxyphenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IDENTIFICATION AND 
CHARACTERIZATION 
 
 
 
 
 
 
 
 
 
 
                 Identification and characterization 
 
                                                              Solubility 
 
             Table  no:2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound code. Soluble in Insoluble in 
1b DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
1e DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
2b DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
2c DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
3b DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
3c DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
3d DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
4b DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
4e DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
5e DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
6b DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
6e DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8a1 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8a2 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8a3 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8b1 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8b2 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8b3 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8c1 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8c2 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8d1 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8d2 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8d3 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
8d4 DMSO, DMF, ethanol, chloroform, acetone CCl4,water 
 
 
 
 
 
 
 
         Thin layer chromatography  
  
Chromatography is an important technique to identify the formation of new 
compounds and also to determine the purity of the compound. The Rf value is 
characteristic for each of the compound. 
a. Preparation of chromatoplate: 
Cleaned and dried glass plates were taken. Uniform slurry of silica Gel-G in water 
was prepared in the ratio 1:2. The slurry was then poured into the chamber of TLC 
applicator, 
Glass plate were moved under the applicator smoothly to get an uniform coating of 
slurry on the plates. 
The plates were dried first at room temperature and then kept for activation at 1100C 
for 1hour. 
b. Preparation  of solvent system and saturation of chamber: 
The solvent system used for development of chromatogram was prepared carefully by mixing. 
Methanol: chloroform [1:1] 
c. Application of sample: 
The solution of parent compounds and its target molecule were taken in small bored 
capillary tube and spotted at 2centimteers from the base end of the plate. After 
spotting the plate will allow to dry at room temperature and plates were transferred to 
chromatogrophic chamber containing solvent system for development. 
d. Development of chromatogram: 
Plates were developed by ascendind technique when solvent front had reached a 
disance of 10-12centimeters; they were taken out and dried at room temperature. 
e. Detection of spots. 
The developed spots were detected by exposing them to iodine vapours. 
f.  Calculation of Rf value: 
Formula for calculating Rf value of synthesized compounds. 
Rf value = Distance travelled by sample / Distance travelled by solvent front. 
 
 
     
 
 
     
  Table no:3 
 
 
Compound code Mobile Phase Ratio Rf value 
1b Methanol: Chloroform 1:1 0.54 
1e Methanol: Chloroform 1:1 0.77 
2b Methanol: Chloroform 1:1 0.56 
2c Methanol: Chloroform 1:1 0.70 
3b Methanol: Chloroform 1:1 0.59 
3c Methanol: Chloroform 1:1 0.66 
3d Methanol: Chloroform 1:1 0.60 
4b Methanol: Chloroform 1:1 0.69 
4e Methanol: Chloroform 1:1 0.66 
5e Methanol: Chloroform 1:1 0.5 
6b Methanol: Chloroform 1:1 0.87 
6e Methanol: Chloroform 1:1 0.64 
8a1 Methanol: Chloroform 1:1 0.73 
8a2 Methanol: Chloroform 1:1 0.53 
8a3 Methanol: Chloroform 1:1 0.73 
8b1 Methanol: Chloroform 1:1 0.65 
8b2 Methanol: Chloroform 1:1 0.65 
8b3 Methanol: Chloroform 1:1 0.74 
8c1 Methanol: Chloroform 1:1 0.67 
8c2 Methanol: Chloroform 1:1 0.56 
8d1 Methanol: Chloroform 1:1 0.54 
8d2 Methanol: Chloroform 1:1 0.76 
8d3 Methanol: Chloroform 1:1 0.65 
8d4 Methanol: Chloroform 1:1 0.76 
 
 
 
                    
 
                     Physical properties of the  synthesized  compounds 
     Table no:4 
Compound 
Code 
Melting.pt.(ºC) % Yield Molecular 
formula 
Molecular 
Weight(gm) 
1b 230-35 90% C15H13N5O3 311.31 
1e 225-30 89% C15H15N5O3S 345.38 
2b 230-35 90% C15H13N5O4 
 
327.29 
2c 240-45 88% C16H16N4O3 
 
312.32 
3b 235-40 91% C15H12ClN5O3 
 
381.45 
3c 230-35 86% C16H15ClN4O2 
 
335.12 
3d 210-15 89% C15H12Cl2N4O 
 
312.13 
4b 215-20 91% C15H12ClN4O2 
 
345.73 
4e 240-45 90% C15H14ClN5O3S 
 
372.83 
5e 230-35 83% C15H14FN5O3S 
 
363.37 
6b 230-35 90% C16H15N6O5 371.33 
6e 215-20 86% C15H14N6O5S 
 
367.60 
8a1 220-25 
 
89% 
 
C15H14ClN5O3S 
 
379.82 
 
8a2 210-15 
 
90% 
 
C15H12Cl2N4O 
 
335.19 
 
8a3 225-30 91% C15H12ClN5O2S 361.81 
8b1 230-35 92% C15H14ClN5O2S2 395.89 
8b2 225-30 
 
89% 
 
C15H12Cl2N4S 
 
351.25 
 
8b3 220-25 90% C15H12ClN5O2S 361.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8c1 230-35 
 
86% C15H14ClN5O2S2 379.18 
8c2 220-25 
 
88% 
 
C15H12Cl2N4S 
 
351.25 
 
8d1 215-20 
 
89% 
 
C15H14N6O4S2 
 
406.44 
 
8d2 220-25 88% C15H12N6O4S 372.36 
8d3 210-15 
 
90% 
 
C15H12ClN5O2S 
 
361.81 
 
8d4 220-25 85% C16H15N5O3S 357.39 
 
 
 
 
 
 
 
 
 
SPECTRAL STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           IR Spectra 
The peak in IR spectrum gives an idea about the functional group and probable structure of 
the compound in IR region ranges between 4000-666 cm-1. Quanta of radiation from this 
region of the spectrum correspond to energy differences between different vibrational levels 
of molecules.The compound was recorded on Jasco FTIR-4100 spectrometer shows different 
vibration levels of molecules by using KBr disk technique. The IR spectrum of compound as 
follows: 
                          Characteristics IR absorption of compounds 
Compound code:    1e 
N
N
ON
H
N
H
H2NO2S
4-({[(5-phenyl-1,3,4-oxadiazol-2-yl)amino]methyl}amino)benzenesulfonamide  
 
                    N-H stretching =3413cm-1, Aromatic Stretching = 2849,1574,750cm-1, 
                                C-N stretching = 1470cm-1, C- O-C stretching = 1094cm-1 
 
Compound code:    2b 
NN
ON
H
N
H
OH
O2N
4-(5-((4-nitrophenylamino)methylamino)-1,3,4-oxadiazol-2-yl)phenol  
 
N-H stretching vibration = 3374 cm-1, Aromatic stretching=2918,1574,738 cm-1 
,N=O Stretching=1512,1344 cm-1 C-O-C stretching = 1043cm-1 
 
 
 
Compound code:    2c 
NN
ON
H
N
H
OH
H3CO
4-[5-({[(4-methoxyphenyl)amino]methyl}amino)-1,3,4-oxadiazol-2-yl]phenol  
 OH Stretching  vibration=3264 cm-1,N-H Stretching =3173 cm-1,Aromatic 
stretching=2873,1654,822cm-1,C-N Stretching=1387 cm-1,C-O-CStretching=1092cm-1 
 
 
                                                       
                                                  Compound code:    3b 
N N
O
H
N
H
N
NO2
Cl
-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-methylphenyl)methanediamineN N  
N-H Stretching=3353 cm-1,Aromatic stretching=2952 cm-1,1688cm-1,763 cm-1, 
          N=O Stretching=1566 cm-1,1372 cm-1,C-N Stretching=1435 cm-1, 
C-O-C Stretching=1234 cm-1,C-Cl=962 cm-1 
 
                                               Compound code:    3c 
N N
O
H
N
H
N
Cl
OCH3
N-((4-methoxyphenylamino)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazol-2-amine  
      N-H Stretching=3430 cm-1,Aromatic Stretching=3310 cm-1,1572 cm-1,740cm-1, 
C-N   Stretching=1423 cm-1,C-O-C Stretching=1161 cm-1, 
  Compound code:    4b 
N N
O
H
N
H
N
Cl
NO2
-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N  
N-H Stretching=3373 cm-1,Aromatic Stretching=3085 cm-1157 cm-1,738cm-1, 
N=O stretching=1511 cm-1,C-O-C Stretching=1043cm-1,C-Cl=862cm-1 
 
                                            Compound code:    5e 
N N
O
H
N
H
N
F
SO2NH2
N-(4-Sulphonamyl)-N-[5-(3-Fluorophenyl)-1,3,4-oxadiazol-2-yl]methanediamine  
                       N-H Stretching=3100 cm-1,Aromatic Stretching=1648 cm-1,821 cm-1, 
               C-F=1387 cm-1,C-N=1319 cm-1,C-O-C Stretching=1092 cm-1,S=O=1050 cm-1 
 
 
 
 Compound code:    6b 
N N
O
H
N
H
N
O2N
NO2
N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-nitrophenylmethanediamine  
N-H Stretching=3374cm-1,Aromatic Stretching=2918cm-1,1618cm-1, 
738cm-1,N=OStretching=1575cm-1,1329cm-1,C-NStretching=1424cm-1, 
C-O-C Stretching=1043cm-1 
 
                                        Compound code:    6e 
N
N
O
N
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
N-H Stretching=2926cm-1,Aromatic Stretching=1597 cm-1,752cm-1 
,N=O Stretching=1507cm-1,1323cm-1,C-N Stretching=1459cm-1,S=O=1050cm-1 
,C-O-C=1096cm-1 
 
                                          Compound code:    8a1 
N N
S
H
N
H
N
Cl
SO2NH2
4-[({[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
Aromatic Stretching=1597cm-1,751cm-1.C-N Stretching=1374cm-1,S=O=1096cm-1,C-
Cl=815 cm-1, 
C-S-C=676 cm-1 
 
                                           Compound code:    8b1 
NN
SN
H
N
H
Cl
H2NO2S
4-[({[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
    N-H Sretching=3136cm-1,Aromatic Stretching=2926 cm-1,1596 cm-1,688cm-1, 
C-N Stretching=1374cm-1,S=O=1050cm-1,C-Cl=822cm-1,C-S-C=688cm-1 
 
 
 
                                       Compound code:    8b3 
N N
S
H
N
H
N
Cl
NO2
-[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]- '-(4-nitrophenyl)methanediamineN N  
                                 N-H Stretching=3373cm-1,Aromatic Stretchihg=1619cm-1,738cm-1, 
        N=O=1574 cm-1329cm-1,C-N=1424cm-1,C-Cl=862cm-1,C-S-C=718cm-1 
 
Compound code:    8c1 
N
N
SN
H
N
H
F
H2NO2S
4-[({[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
                                              N-H Stretching=3100cm-1,Aromatic  
Stretching=2920cm1,1595cm1,C-F=1450cm-1, C- N=1318cm-1,C=S=1091cm-1, 
                                                   C-S-C=908 cm-1 
 
  Compound code:    8d1 
N
N
S
N
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide  
        N-H Stretching=3100cm-1,Aromatic Stretching=2920 cm-1,1596 cm-1,815cm-1, 
N=O=1520 cm-1,1323 cm-1,S=O=1151 cm-1,C-S-C=750 cm-1 
 
 
Compound code:    8d2 
N
N
S
N
HNH
NO2
O2N
-(4-nitrophenyl)- '-[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]methanediamineN N  
              Aromatic nitro = 1542.77cm-1,N-H Stretching-3373cm-1, 
Aromatic Stretching=2920 cm-1,1618cm1,738cm-1, 
             N=O=1575 cm-1,1329cm-1,C-N=1448cm-1,C-S-C=862cm-1 
 
 
 
 
 
                                                          1HNMR Spectr 
  
NMR spectroscopy enables us to record differences in magnetic properties of the various 
magnetic nuclei present, and to deduce in large measure about the position of these nuclei are 
within the molecule. We can deduce how many different kinds of environment are there in 
the molecules and also which atom is present in neighboring groups. The proton NMR 
spectra enables us to know different chemical and Magnetic environment corresponding to 
proton in molecules.    
  
Table no.6  
Ser. No. Comp. 
code 
Hydrogen δ(ppm) 
 
Multiplicity Solvent 
1 1b (2H,Ar-H,Ortho to 
nitro) 
7.93-7.95 Doublet DMSO 
(5H,Ar-H) 7.49-7.52 Multiplet 
(2H,Ar-H) 6.90-6.91 Doublet 
(1H,Ar-NH) 6.72 Singlet 
(2H,CH2) 3.53 Singlet 
(1H,Oxazole-NH) 2.50 Singlet 
2 4e (1H,Ar-NH) 7.95 Singlet DMSO 
(4H,Ar-H) 7.80-7.81 Multiplet 
(4H,Ar-H) 7.78-7.79 Multiplet 
(4H,Ar-H) 7.78-7.79 Multiplet 
(2H,NH2) 7.65 Singlet 
(1H,Oxazole-NH) 2.89 Singlet 
3 6b (4H,Ar-H) 8.73-8.75 Doublet DMSO 
(4H,Ar-H) 8.03-8.05 Doublet 
(1H,Ar-NH) 6.73-6.76 Singlet 
(2H,CH2) 3.34 Singlet 
(1H,Oxazole-NH) 2.50 Singlet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 6e (4H,Ar-H) 7.40-7.61 Multiplet DMSO 
(4H,Ar-H) 7.29 Multiplet 
(1H,Ar-NH) 6.74 Singlet 
(2H,CH2) 3.34 Singlet 
(1H,Oxazole-NH) 2.89 Singlet 
5 8d1 (4H,Ar-H) 8.41-8.437 Doublet DMSO 
(4H,Ar-H) 8.16-8.18 Doublet 
(1H,Ar-NH) 7.958 Singlet 
(2H,NH2) 7.95 Singlet 
(2H,CH2) 3.34 Singlet 
(1H,Oxazole-NH) 2.89 Singlet 
 
 
 
 
 
 
Mass spectroscopy 
Mass spectroscopy enables us to know; 
Relative molecular masses (molecular weight) with very high accuracy, from this exact 
molecular formula can be deduced. To detect within the molecule the places at which it 
prefers fragmentation, from these we can deduce the presence of recognizable groups within 
the molecule. As a method of identifying analytes by comparison of their mass spectra with 
libraries of digitalized mass spectra of known compound. 
The spectral data of synthesized compounds as follows: 
 
Table no.7 
Sr. no. Compound code Molecular mass (in gram) 
1 1b 311.03 
2 4e 372.8 
3 6b 396.2 
4 6e 390.6 
5 8a1 379.82 
6 8b3 361.81 
7 8c1 379.18 
8 8d1 406.44 
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N N
O
H
N
H
N
NO2N-((4-nitrophenylamino)methyl)-5-phenyl-1,3,4-oxadiazol-2-amine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O
H
N
H
N
Cl
SO2NH2
4-[({[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O
H
N
H
N
O2N
NO2
N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-nitrophenylmethanediamine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NN
ON
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N
S
N
HNH
NO2
H2NO2S
4-[({[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N
SN
H
N
H
F
H2NO2S
4-[({[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]amino}methyl)amino]benzenesulfonamide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
BIOLOGICAL ACTIVITY 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIOLOGICAL ACTIVITY 
The newly synthesized compound were screened for their in Vitro antimicrobial activity 
against bacterias such as Escherichia coli, Pseudomonas aureginosa, Rhodosporum rubrum, 
Vibrio cholera, Monococcus leuteus, Staphylococcus aureus, Bacillus substiles, and 
Corynebacterium typhi etc. whereas Antifungal activity was screened by fungus such as 
Candida albicans, Monococcus purpurea, Aspergillus Niger,  and Trycophytan rubrum etc  
was used. 
1. Zone of inhibition (disc diffusion method) 
2. Minimum inhibitory concentration (serial dilution method) 
Antibacterial activity 
Disc diffusion method: 
Disc diffusion method was used for determination of preliminary antibacterial or antifungal 
activity. The disc diffusion method, the drug potency is based on measurement of the 
diameter of the zone of inhibition surrounding cylinder discs. 
In disk diffusion method each disk was dipped into 100 micro gram concentration of 
synthesized compound for around 1hr. The procedure for carrying out disc diffusion method 
is as follows. 
Preparation of inoculums:  
Preparation of inoculums of bacteria was carried out by preparing Mueller Hinton Broth and 
transferred to test tube, keep it for sterilization in autoclave at 121 c for 15 min. then add 
culture of each bacteria to each tube (this step is carried out in aseptic room near laminar air 
flow) then keep it for incubation in incubator for 18-24 hrs  at 37 c. 
 
 
 
 
Procedure: 
Mueller Hinton agar was prepared by adding 21gm of Mueller Hinton agar in 1000 ml of 
distilled water and add agar-agar 1-2 gm for solubilization.cover and keep it for sterilization 
in autoclave for 121 c for 15 mins. After cooling take it to aseptic room near Laminar air 
flow.Take a sterile Petridish  and divide  it into  4 or 6 quadrant. Pass the molten nutrient agar 
(Mueller Hinton agar) into Petridish and allow it to solidify for 10 min. Swab the organism 
over the molten nutrient agar. Place the disc of known concentration in a corner of each 
quadrant and disc of standard drug in the start. Incubate the Petridish at 37ºc for 1hrs in 
inverted position to allow disc diffusion as well as to half the growth of microorganism. 
Measure the zone of inhibition of all drugs in millimeter. 
 
Measurement of minimum inhibitory concentration 
Dilution method:  
Preparation of test drug: 
Serial dilution of the test Antimicrobial agent was made in 1ml of Mueller Hinton broth test 
series of 1-8 dilution. 
Preparation of inoculums 
Overnight culture grown at 37°c in Mueller Hinton broth and keep it at 37°c for 24 hrs in 
incubator. 
Procedure: 
Prepare Mueller Hinton both by formula: 
       Mueller Hinton    2.1g 
 Water                  100ml 
Take 8 MIC tubes ,labeled it as number 1-8 and transfer 1ml of broth to each tube, add 1ml of 
synthesized compound to first tube  and then transfer 1ml from first tube to second ,so 
 
 
similarly transfer 1ml from each tube to second tube up to 7th tube and 8th tube kept as 
controlled i.e. without drug. To all tube add 0.1ml of culture (bacterial) up to 8th tubes. All the 
tubes were incubated at 37°C for 24 hrs. After incubation observed the turbidity. The tube 
which shows turbidity and the tube which is before that tube and whose conc. are called as 
minimum inhibitory concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table no.8 
code 
 
Conc. (in µg) Zone of inhibition(in millimeter) 
Escherichia 
coli 
(Gram - ve) 
Pseudomonas.
aeruginosa 
(Gram - ve) 
Rhodosporm 
rubrum 
(Gram - ve) 
Vibrio 
cholerae 
(Gram - ve) 
3b 100 8 15 14 17 
3c 100 7 13 11 8 
3d 100 15 18 10 18 
4b 100 11 15 7 9 
4e 100 7 14 8 11 
6b 100 6 16 5 10 
8a1 100 13 15 7 17 
8a2 100 12 20 23 19 
8b1 100 11 11 15 14 
8c1 100 15 13 17 16 
8d1 100 16 15 20 19 
Sparfloxacin 100 25 20 26 25 
 
 
 
Table no.9 
 
 
code 
 
 
Conc. (in µg) 
Zone of inhibition(in millimeter) 
Monococcus 
luteus 
(Gram + ve) 
Staphylococcus
aureeus 
(Gram + ve) 
Bacillus 
substiles 
(Gram + ve) 
Corynebacterm 
typhi 
(Gram + ve) 
3b 100 15 15 14 20 
3c 100 10 9 11 11 
3d 100 8 11 9 25 
4b 100 14 16 7 20 
4e 100 12 13 11 10 
6b 100 10 8 9 9 
8a1 100 12 11 11 10 
8a2 100 18 18 14 19 
8b1 100 11 11 12 11 
8c1 100 10 10 18 12 
8d1 100 26 23 27 25 
Sparfloxacin 100 30 25 30 30 
 
 
 
 
 
 
 
 
 
 
    Table no.10 
Escherischia coli 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - + + + + + + 
3c - - + + + + + + 
3d - + + + + + + + 
4b - + + + + + + + 
4e - - - + + + + + 
6b - - + + + + + + 
8a1 - - - - - + + + 
8a2 - - - - + + + + 
8b1 - - - - + + + + 
8c1 - - - - - + + + 
8d1 - - - - - + + + 
    Table no.11 
Pseudomonas aeruginosa 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - + + + 
3c - - - - + + + + 
3d - - - - - + + + 
4b - - - - + + + + 
4e - - - + + + + + 
6b - - - - + + + + 
8a1 - - - - - + + + 
8a2 - - - - - + + + 
8b1 - - - - + + + + 
8c1 - - + + + + + + 
8d1 - - - - - + + + 
 
 
 
 
 
 
   Table  no.12 
 
Rhodosporum ruprum 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - + + + + 
3c - - - + + + + + 
3d - - + + + + + + 
4b - + + + + + + + 
4e - - - + + + + + 
6b - - + + + + + + 
8a1 - - + + + + + + 
8a2 - - - - + + + + 
8b1 - - - - - + + + 
8c1 - - - - - + + + 
8d1 - - - - - + + + 
    Table  no.13 
Vibryo cholerae 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - - + + 
3c - - + + + + + + 
3d - - - - - - + + 
4b - + + + + + + + 
4e - - - + + + + + 
6b - - + + + + + + 
8a1 - - - - - + + + 
8a2 - - - - - - + + 
8b1 - - - - + + + + 
8c1 - - - - - + + + 
8d1 - - - - - - + + 
  
 
 
   Table no.14 
Monococcus leuteus 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - + + + 
3c - - + + + + + + 
3d - - - - - + + + 
4b - - - - - + + + 
4e - - + + + + + + 
6b - + + + + + + + 
8a1 - - + + + + + + 
8a2 - - - - - - + + 
8b1 - - - + + + + + 
8c1 - - + + + + + + 
8d1 - - - - - - + + 
    Table no.15 
Staphylococcus  aureus 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - - + + 
3c - - - + + + + + 
3d - - - + + + + + 
4b - - - - - - + + 
4e - - - - + + + + 
6b - - + + + + + + 
8a1 - - - - + + + + 
8a2 - - - - - + + + 
8b1 - - - - + + + + 
8c1 - - - - + + + + 
8d1 - - - - - - + + 
 
 
 
 
 
 
 
 
 
 
 
  Table no.16 
 
Bacillus substiles 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - - + + 
3c - - - - - + + + 
3d - - - + + + + + 
4b - + + + + + + + 
4e - - - - - + + + 
6b - - + + + + + + 
8a1 - - - + + + + + 
8a2 - - - - - + + + 
8b1 - - - - - + + + 
8c1 - - - - - - + + 
8d1 - - - - - - + + 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Table no.17 
Corneybacterium typhi 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - - + + + 
3c - - - - + + + + 
3d - - - - - - + + 
4b - - - - - + + + 
4e - - - - + + + + 
6b - - + + + + + + 
8a1 - - - + + + + + 
8a2 - - - - + + + + 
8b1 - - - - + + + + 
8c1 - - - - - + + + 
8d1 - - - - - - + + 
 
(-) Indicates = No turbidity, 
                               (+) indicates = Turbidity, 
Solvent = Dimethylsulfoxide 
 
 
 
 
 
 
 
 
 
 
 
 
           
  
 
 
 
 
           
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
Antibacterial evaluation 
of compounds  against  
E.coli 
Antibacterial  evaluation 
of  compounds  against 
P. aeruginosa 
Antibacterial  evaluation 
of compounds  against 
P. aeruginosa 
Antibacterial evaluation 
of  compounds against 
R.rubrum 
Antibacterial evaluation of  
compounds against 
V.Cholerae 
 
Antibacterial evaluation of  
compounds against 
M.luteus 
Antibacterial evaluation 
of  compounds against 
S.aureus 
Antibacterial evaluation of  
compounds against 
B.substilus 
Antibacterial evaluation of  
compounds against 
C.typhi 
 
 
 
 
   
Minimum inhibitory concentration against  E.coli 
 
 
Minimum inhibitory concentration against  P. aeruginosa 
 
 
Minimum inhibitory concentration against  R.rubrum 
 
 
 
 
Minimum inhibitory concentration against V.Cholerae 
 
 
 
Minimum inhibitory concentration against M.luteus 
 
 
 
 
Minimum inhibitory concentration against S.aureus 
 
 
 
 
 
 
 
 
 
 
Minimum inhibitory concentration against B.substiles 
 
 
 
 
 
 
Minimum inhibitory concentration against C.typhi 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antifungal activity: 
Disc diffusion method 
Disc diffusion method was used for determination of preliminary antibacterial or antifungal 
activity. In disk diffusion method each disk was dipped into 100 micro gram concentration of 
synthesized compound for around 1hr. the procedure for carrying out disc diffusion method is 
as follows: 
Preparation of inoculums: 
Preparation of inoculums of fungus was carried out by preparing subarrod dextrose Broth and 
transferred to test tube, keep it for sterilization in autoclave at 121°c for 15 min. then add 
culture of each fungi to each tube (this step is carried out in aseptic room near laminar air 
flow) then keep it for incubation in incubator for 24-48 hrs. at 29°c. 
Procedure: 
Subarrod Dextrose Broth was prepared by adding 1g of peptone and 4g of dextrose in 100 ml 
of distilled water. Cover and keep it for sterilization in autoclave for 121°c for 15 min. After 
cooling take it  to aseptic room near Laminar air flow .Take a sterile Petridish and divide  it 
into. 4 or 6 quadrant. Pass the Subarrod Dextrose Broth into Petridish and allow it to solidify 
for 10 min. Swab the organism over the molten nutrient agar. Place the disc of known 
concentration in a corner of each quadrant and disc of standard drug in the start. Incubate the 
Petridish at 37°c for 1hrs in inverted position to allow disc diffusion as well as to half the 
growth of microorganism. Incubate the Petridish at 29°c for 24-48 hrs. in inverted position. 
Measure the zone of inhibition of all drugs in millimeter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measurement of minimum inhibitory concentration 
Dilution method: 
Preparation of test drug: 
Serial dilution of the test Antimicrobial agent was made in 1ml of Subarrod Dextrose Broth 
test series of 1-8 dilution. 
Preparation of inoculums 
Overnight culture grown at 29°C in Subarrod Dextrose Broth and keep it at 29°C for 24-48 
hrs. in incubator. 
Procedure: 
Prepare Subarrod Dextrose Broth by formula: 
Peptone         1g 
Dextrose        4g 
Water             100ml 
 
Take 8 MIC tubes, labeled it as number 1-8 and transfer 1ml of broth to each tube. add .then 
add 1ml of drug to first tube then transfer 1ml from first tube to second so similarly transfer 
1ml from each tube to second tube up to 7th tube and 8th tube kept as controlled i.e. without 
drug. To all tube add 0.1ml of culture (fungi) up to 8th tubes. All the tubes were incubated at 
29°C for 24-48 hrs. After incubation observed the turbidity. The tube which shows turbidity 
the tube which is before that tube and whose conc. are called as minimum inhibitory 
concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table no.18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Compound 
Code 
Concentration 
(in µg )  
Zone of inhibition  in millimeter 
Candida 
albicans 
Monococcus 
purpurea 
Aspergillus 
niger 
Trycophytan 
rubrum 
3b 100 µg 6 8 8 5 
3c 100 µg 8 8 6 6 
3d 100 µg 7 7 5 8 
4b 100 µg 6 5 9 8 
4e 100 µg 11 9 7 15 
6b 100 µg 7 6 16 10 
8a1 100 µg 10 9 13 13 
8a2 100 µg 17 11 13 18 
8b1 100 µg 14 11 11 14 
8c1 100 µg 11 10 10 14 
8d1 100 µg 13 10 11 12 
Clotrimazole 100 µg 15 12 19 20 
 
 
 
Table no.19 
Candida albicans 
Test tube no.  2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - + + + + + 
3c - - + + + + + + 
3d - - + + + + + + 
4b - + + + + + + + 
4e - - - - - + + + 
6b - - + + + + + + 
8a1 - - - + + + + + 
8a2 - - - - + + + + 
8b1 - - - - + + + + 
8c1 - - - - + + + + 
8d1 - - - - - + + + 
  Table no.20 
Monococcus purpurea 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - + + + + 
3c - - - - + + + + 
3d - - - + + + + + 
4b - + + + + + + + 
4e - - - - - + + + 
6b - - + + + + + + 
8a1 - - - + + + + + 
8a2 - - - - - + + + 
8b1 - - - - + + + + 
8c1 - - - - + + + + 
8d1 - - - - - + + + 
  
 
 
 
 
 Table no.21 
Aspergillus niger 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - + + + + 
3c - - - - - + + + 
3d - - - - - + + + 
4b - - - - - + + + 
4e - - - - - - + + 
6b - - - - - - + + 
8a1 - - - - - + + + 
8a2 - - - - - + + + 
8b1 - - - - - - + + 
8c1 - - - - - - + + 
8d1 - - - - - + + + 
  Table no.22 
Monococcus rubrum 
Test tube no. 1 2 3 4 5 6 7 8 
concentration 100 50 25 12.5 6.25 3.125 1.5625 Controlled 
3b - - - - + + + + 
3c - - - - - + + + 
3d - - - - - + + + 
4b - - - - - + + + 
4e - - - - - - + + 
6b - - - - - - + + 
8a1 - - - - - + + + 
8a2 - - - - - + + + 
8b1 - - - - - + + + 
8c1 - - - - - - + + 
8d1 - - - - - + + + 
 
 
 
 
 
 
(-) Indicates = No turbidity, 
  (+) indicates = Turbidity, 
                                                 Solvent = Dimethylsulfoxide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
          
 
 
 
 
 
 
 
 
                            
 
 
 
 
 
 
 
 
Antifungal evaluation of  
compounds against 
M.rubrum 
Antifungal evaluation of  
compounds against  
M.rubrum 
Antifungal evaluation of  
compounds against 
C.albicans 
 
Antifungal evaluation of  
compounds against 
C.albicans 
 
Antifungal evaluation of  
compounds against 
M.purpurea 
Antifungal evaluation of  
compounds against 
M.purpurea  
 
Antifungal evaluation of  
compounds against  
A.niger 
 
Antifungal evaluation of  
compounds against  
A.niger 
 
 
 
 
 
Minimum inhibitory concentration against C.albicans 
 
 
 
 
 
Minimum inhibitory concentration against  M.purpurea 
 
 
 
 
 
 
 
 
 
 
 
Minimum inhibitory concentration against   A.niger 
 
 
 
 
 
 
Minimum inhibitory concentration against  M.rubrum 
 
 
 
 
 
 
 
 
IN VITRO ANTI CANCER ACTIVITY 
The human cervical cancer cell line (HeLa) and mouse embryonic fibroblasts cell line 
(NIH 3T3) were obtained from National Centre for Cell Science (NCCS), Pune. The HeLa 
cells were grown in Eagles Minimum Essential Medium containing 10% fetal bovine serum 
(FBS) and NIH 3T3 cells were grown in Dulbeccos Modified Eagles Medium (DMEM) 
containing 10% FBS. All cells were maintained at 370C, 5% CO2, 95% air and 100% relative 
humidity. Maintenance cultures were passaged weekly, and the culture medium was changed 
twice a week. 
Cell treatment procedure 
 The monolayer cells were detached with trypsin-ethylenediaminetetraacetic acid 
(EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium with 5% FBS to give final density of 1x105 
cells/ml. one hundred microlitres per well of cell suspension were seeded into 96-well plates 
at plating density of 10,000 cells/well and incubated to allow for cell attachment at 370C, 5% 
CO2, 95% air and 100% relative humidity. After 24 h the cells were treated with serial 
concentrations of the extracts and fractions. They were initially dissolved in neat 
dimethylsulfoxide (DMSO) and further diluted in serum free medium to produce five 
concentrations. One hundred microlitres per well of each concentration was added to plates to 
obtain final concentrations of 100, 10, 1.0 and 0.1 µM. The final volume in each well was 
200 µl and the plates were incubated at 370C, 5% CO2, 95% air and 100% relative humidity 
for 48h. The medium containing without samples were served as control. Triplicate was 
maintained for all concentrations. 
MTT assay 
 MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in living 
cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the MTT to an 
 
 
insoluble purple formazan. Therefore, the amount of formazan produced is directly 
proportional to the number of  viable cells.After 48h of incubation, 15µl of MTT (5mg/ml) in 
phosphate buffered saline (PBS) was added to each well and incubated at 370C for 4h. The 
medium with MTT was then flicked off and the formed formazan crystals were solubilized in 
100µl of DMSO and then measured the absorbance at 570 nm using micro plate reader. The 
% cell inhibition was determined using the following formula.  
% cell Inhibition = 100- Abs (sample)/Abs (control) x100  
Nonlinear regression graph was plotted between % Cell inhibition and Log10 
concentration and IC50 was determined using GraphPad Prism software.[67,68] 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table no.23  Absorbance of various concentration of samples at 570 nm in HELA cell 
line.  
 
Code 
 
Conc  (µM) 0.1 1 10 100 Cont IC50 
(µM) 
 
 
 
1b 
 
ABS 0.414 0.386 0.368 0.276 0.426 
> 100  
 0.413 0.384 0.373 0.288 0.391 
 0.395 0.404 0.372 0.277 0.415 
Avg 0.407333 0.391333 0.371 0.280333 0.41066 
% cell inhibition 0.811688 4.707792 9.659091 31.73701  
 
 
4e 
ABS 0.39 0.388 0.37 0.337 0.426 
> 100  
 0.404 0.4 0.383 0.326 0.391 
 0.41 0.398 0.366 0.318 0.415 
Avg 0.401333 0.395333 0.373 0.327 0.410667 
% cell inhibition 2.272727 3.733766 9.172078 20.37338  
 
 
 
 
 
 
 
 
 
 
 
 
Table no.24  Absorbance of various concentration of samples at 570 nm in normal  cell 
line.  
 
 
Code 
 
Conc  (µM) 0.1 1 10 100 Cont IC50 
(µM) 
 
 
 
1b 
 
ABS 0.145 0.239 0.219 0.155 0.245 
> 100  
 0.241 0.241 0.215 0.164 0.248 
 0.244 0.238 0.211 0.17 0.247 
Avg 0.21 0.239333 0.215 0.163 0.246667 
% cell inhibition 14.86486 2.972973 12.83784 33.91892  
 
 
4e 
ABS 0.25 0.235  0.214 0.093 0.245 
> 100  
 0.243 0.242 0.211 0.116 0.248 
 0.242 0.237 0.216 0.111 0.247 
Avg 0.245 0.238 0.213667 0.106667 0.246667 
% cell inhibition 0.675676 3.513514 13.37838 56.75676  
        
                         
 
 
Anti-Tubercular Activity of Synthesized Compounds 
       The REMA(Resazurin  microplate assay) plate method was performed to determine the 
MICs of test compounds for all the Mycobacterium isolates briefly, a 100 ml volume of 
Middle brook 7H9 broth (Difco, USA) was dispensed in each well of a 96-well cell culture 
plate (Nunc, Denmark). Test compound concentrations prepared directly in the medium were 
1, 10,100 µg/ml. Perimeter wells of the plate were filled with sterile water to avoid 
dehydration of the medium during incubation. A standard bacterial suspension equivalent in 
turbidity to that of a no. 1 McFarland standard was prepared and diluted 1:20 in 7H9 broth; 
a100 mL inoculum was used to inoculate each well of the plate. A growth control containing 
no test compound and a sterile control without inoculum were also included. Plates were 
sealed and incubated at 37ºC for 1 week. Twenty-five microlitres (25µL of 0.02%  Resazurin 
(Sigma Chem. Co.) Solution was added to each well; plates were re-incubated for an 
additional 2 days. A change in colour from blue to pink indicated the growth of bacteria, and 
the MIC was read as the Minimum test compound concentration that prevented the color 
change in Resazurin solution.[69,70,71] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay-REMA 
Test organism: Mycobacterium tuberculosis  
 
 
 
 
Sr.no. Compound code Concentration 
  1µg/ml 10µg/ml 100µg/ml 
1 3d N N N 
2   3b N N P 
3 8d1 N N N 
4 8a2 N P P 
5 8a1 N N P 
6 Rifampicin P P  
7 control N N  
 
N=No  inhibition 
P=Inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS ANDDISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
The title compounds were synthesized in 3 steps process: 
 
 In the  first  step 
Synthesis  of titled compound was started from substituted aromatic aldehyde, which upon 
reaction with semicarbazides and thiosemicarbazide  in alcohol to form semicarbazone and 
thiosemicarbazone respectively. 
  
 In the  second  step 
 Semicarbazone  and  thiosemicarbazone was suspended in   warm water; ferric chloride  in   
warm water was added quantitatively, slowly with constant stirring. The contents were heated 
at 100°C for 2hrs. Solution was filtered and citric acid , sodium carbonate  were added. The 
obtained mixture was divided in to four portions and each portion was neutralized with 
ammonia respectively. The precipitate obtained was recrystallized from alcohol.                          
 
 In the third step  
The  2-amino-5-substituted-1, 3, 4-oxadiazole  and  2-amino-5-substituted-1,3,4-thiadiazole  
were undergoes mannich reaction with substituted aniline and formaldehyde to get mannich 
base 2-amino 5-substituted 1, 3, 4- oxadiazole and 2-amino 5-substituted 1, 3, 4-  thiadiazole 
derivatives respectively. 
 
Melting point  
The melting point   of  the  synthesized  compounds were found by an open capillary tube 
method using campbell electronics model-C-CMP-1 melting point apparatus and or 
uncorrected. 
 
 Characterization of synthesized compounds 
Solubility 
The solubility of all compounds was tested by using following solvents.  
 Chloroform, ethanol, DMSO, DMF, acetone, etc.(soluble) 
 Water, CCl4, etc (insoluble) 
 
 
 
Thin layer chromatography:  
The purity of synthesized compounds and conformation of the reaction were analyzed by thin 
layer chromatography technique using silica gel-G (G=gypsum binder) as stationary phase, 
employing methanol : chloroform (1:1) as mobile phase, spots were visualized in iodine 
vapour. 
The Rf value were calculated by using formula: 
 
 Rf value = distance travelled by sample/distance travelled by solvent front 
 
Infrared spectra 
The infrared spectrums of the synthesized compounds were given in detail. The formations of 
C-O-C in the compounds were clearly observed in all the spectra. the absence of COOH- 
peak is also a evidence for the formation of compounds 
From the structure investigation, IR spectra showed the stretching frequency range between 
1042-1234cm-1, which evidenced the presence of C-O-C group  and 676-908cm-1  which  
showed  the  presence  of  C-S-C  group. 
 
 
Nuclear magnetic resonance spectra 
NMR spectra of all the compounds were given. It shows the characteristic peak for the 
formed compounds. 
1HNMR spectra give a characteristic proton resonance shift for all the synthesized 1,3,4- 
oxadiazole  and  1,3,4-thiadiazole derivatives which ensured the existence of aromatic or 
substituent proton. 
 
Mass spectra  
Mass spectra of synthesized were taken and it is giving almost same molecular weight as that 
of calculated molecular weight. 
 
 
 
 
 
 
 
Biological activity: 
           The zone of inhibition and Minimum inhibitory concentration of the synthesized 
compounds were tabulated. All the synthesized compounds have showed an excellent activity 
against both Gram positive and negative bacteria and fungi. 
 
Antibacterial screening 
       The antibacterial screening of some compounds showed an excellent zone of inhibition 
like compounds  8a1,8a2,8b1,8c1 and 8d1 showed excellent activity against  all  bacterial 
strains. Compounds 3d  showed significant activity against P.aureginosa, V.cholerae and 
C.typhi and 4b Was found to be comparable activity against  S.aures  and C.typhi. 
Antifungal screening 
   The antifungal screening of  synthesized compounds showed  excellent zone of inhibition 
like8a1,8a2,8b1 and 8c1  against all pathogenic fungal strains. The compounds 4e and 6b was 
found to be highly active against  M.rubrum and A.niger.  Compounds  3c, 3d and 4b showed 
moderate activity against  all pathogenic strains. 
Anticancer screening 
      The in vitro anticancer studies were performed for two compounds using MTT assay 
against HeLa cell line  and normal cell line. The compounds 1b and 4e shown  no cytotoxic 
activity  and IC50  value  is greater than 100 µM  . 
Antitubercular screening 
     In vitro antitubercular screening of six compounds which showed significant antibacterial 
and antifungal activity were studied by   REMA  which revealed the compounds  8a2  showed 
significant antimycobacterial activity at a concentration of 10 µg/ml. Compounds 8a1 and 3b  
possessed antimycobacterial activity at a concentration of 100 µg/ml. The compound 8d1 
showed lack of antimycobacterial activity against  Mycobacterium tuberculosis H37Rv strain. 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION 
Synthesis of titled compound was started from substituted aromatic aldehyde, which upon 
reaction with semicarbazides and thiosemicarbazide in alcohol to form semicarbazone and 
thiosemicarbazone respectively. Semicarbazone and thiosemicarbazone was suspended in 
warm water; ferric chloride in  warm water was added quantitatively, slowly  constant stirring 
with respectively. The contents were heated at 100°C for 2hrs. Solution was filtered and citric 
acid sodium carbonate  were added. The obtained mixture was divided in to four portions and 
each portion was neutralized with ammonia. The precipitate obtained was recrystallized from 
alcohol. The 2-amino-5-substituted-1,3,4-oxadiazole and 2-amino-5-substituted1,3,4-
thiadiazole  respectively were undergoes mannich reaction with substituted aniline and 
formaldehyde to get mannich base 2-amino 5-substituted 1,3,4-oxadiazole derivatives and 2-
amino 5-substituted-1,3,4- thiadiazole derivatives respectively.  
The melting point and Rf value of the synthesized compounds indicating the physical 
properties and purity of compounds. 
The structure of the synthesized compounds has been analyzed by Infrared spectra, NMR 
spectral studies and Mass spectral data’s. The data’s of analytical spectra were correlating 
with structures of synthesized compounds. 
 The compound 4-[({[5-(-4-nitrophenyl)-1,3,4-thiadiazol-2yl]amino}methyl) 
amino]benzene sulphonamide (8d1) showed could serve a novel template for bacterial 
infection chemotheraphy. 
N
N
S
N
HNH
NO2
H2NO2S
(8d1) 
 
 The compound N-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]-N1-nitrophenylmethane diamine  
(6b) may be potential candidate for new antifungal agent. 
 
                  
N N
O
H
N
H
N
O2N
NO2 (6b) 
 
 
 
 
 The compounds  (8a1, 8a2, 8b1, and 8c1) exhibited  significant antibacterial  and antifungal  
activities. 
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         (8b1)     
NN
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 Two compounds (1b, 4e) were tested against HeLa,normal cell  and IC50 value  is  found to be 
74.55 µM and  the synthesized  compounds  show  no  cytotoxicity and the  compound  will 
be   safe  for   anticancer   activity. 
 Compound N-(4-chlorophenyl)-N1-[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl)methane diamine 
(8a2)  showed significant antimycobacterial activity at a concentration of 10 µg/ml against  
Mycobacterium tuberculosis H37Rv strain. 
 
N N
S
H
N
H
N
Cl
Cl
(8a2) 
   
                         The entire study reveals that there is wide scope of modifications possible for  
1,3,4-oxadiazole  and  1,3,4-thiadiazole ring system. Oxadiazole and  thiadiazole ring system 
could be incorporated into many more ring systems which itself have their own activity and 
could lead to more potent and highly active compounds. The emphasis should be laid on 
some other activities also such as  Antialzheimer, Anticonvulsant, Antineoplastic, Antiviral, 
Pesticidal, Anti-inflammatory etc. Many new methods could be developed by using different 
solvents and substituent’s. Recent interest was shown by Synthesizing the 1,3,4-oxadiazoles  
and  1,3,4-thiadiazoles by Microwave synthesis. 
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